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ABSTRACT
The mechanism of reversion of adenovirus-transformed cells
in response to the sélection of drug-resistant variants résistant
to methylglyoxal-bis-(guanylhydrazone) was studied. The results
presented here suggest that there is no direct relationship
between development of MGBG résistance and cellular
detransformation. Ail MGBG résistant variants displayed the
transformation revertant phenotype in that these cell lines (i)
had a flat morphology, (ii) exhibited anchorage-dependence, (iii)
did not produce tumors in nude mice and (iv) possessed the viral
transforming genes integrated into the cellular genome.
The présent study deals principally with investigating the
basis of drug-resistance and the cause of detransformation in
these MGBG^-variants. Drug résistance in these cells may have
resulted from two possible events: (a) the target enzyme, SAM-
decarboxylase, may be altered leading to development of
résistance to MGBG, or (b) the cell has an altered drug transport
System. None of the MGBG-resistant variants were altered in the
SAM-decarboxylase. By contrast, analysis of the transport
mechanism showed a decreased influx of MGBG, and no change in the
efflux rate. These results demonstrate that these cells are
transport mutants that are defective in MGBG uptake.
Detransformation could have been brought about through three
différent ways: (a) loss or inactivation of the adenovirus
transforming genes, (b) mutation in a cellular gene required for
transformation and (c) activation of a cellular tumor suppressor
gene. Three of the cell Unes studied came under category (a) :
The G4F cell line had lest the integrated viral transforming
genes. The G2a and G5 cell lines had undergone a mutation which
prevented the transcription of the viral transforming genes.
None of the cell lines exhibited the properties of a cell line
expected of those in category (b). Finally, a single cell line,
G2 exhibited the properties of a cell line with an activated
tumor suppressor gene. This conclusion was based on the
following expérimental observations: (1) G2 cells expressed a
biologically active Ela transforming protein as shown by (i)
résistance to retransformation by Ela plasmids, (ii) positive
complémentation of an Ela deletion mutant, and (iii) Ela-mediated
tumor necrosis factor cytolysis, and (2) somatic cell
hybridization between the parental transformed F4 cell line and
the detransformed G2 cell line resulted in hybrids which were
non-tumorigenic. These hybrids had about double the number of
chromosomes, carried both parental drug-resistance markers and
expressed Ela proteins.
Thus, the G2 cell line belongs to the class of recently
reported revertants that resuit from activation of a dominant
transformation-suppressor gene(s).
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INTRODUCTION
CARCINOGENESIS
It is well established that malignant cell transformation is
a multistep process (Klein and Klein, 1985). Each step in the
process involves the interaction of one or more activated or
constitutively expressed oncogenes and appropriate cellular genes
(Spandidos and Anderson, 1987). More than one pathway leads to
transformation of the cell and each pathway is controlled by a
differentiation program which the oncogenes must alter or block
(Alt et al.,1981; Weissman and Aaronson, 1983).
In spite of the immense knowledge that has been
accumulated about oncogenes and the proteins they specify, little
is known about cellular interactions of the proteins and the
mechanism(s) by which they transform cells (Bishop, 1983).
1. Cellular genes involved in transformation
There is evidence suggesting cellular genes interact with
viral oncogenes (in this study the adenoviral El genes) to bring
about the transformed phenotype (Duesberg, 1987; Sachs, 1987),
and there are cellular genes capable of suppressing oncogenes.
There is compelling evidence showing the existence of cellular
genes capable of regulating or suppressing the transformed state
(Green and Wyke, 1985; Klein and Klein, 1985; Knudson, 1985;
Murphree and Benedict, 1984; Sager, 1986; Weissiaan et al., 1987).
The strongest expérimental evidence supporting the concept
that malignant cell transformation involved the expression of
defects in a cellular mechanism was derived from studies in which
fusion of tumor cells with normal diploid cells resulted in
isolation of hybrids that were suppressed in their tumorigenic
potential. This implies normal chromosomes from nontumorigenic
cells contain elements capable of suppressing tumorigenicity
(Harris et al., 1969; Klinger and Shows, 1983; Sager, 1986;
Stanbridge et al., 1982; Weissman et al., 1987). Recently,
molecular cloning of the DNA sequences that suppress
tumorigenicity confirmed the existence of such genes (Kitayana et
al., 1989; Noda et al., 1989; Schaefer et al., 1988). A loss of
function rather than a dominant gene activâtion or altération (as
with oncogene studies) appears to be associated with malignancy
progression. Several approaches were examined in an attempt to
illustrate the existence of this regulatory function (Bassin and
Noda, 1987). Changes in cellular gene expression following
transformation has been one of them (Hinds et al., 1987, Johnson
et al., 1987, Leof et al., 1987, O'Hara et al., 1987, Owen and
Ostrowski, 1987, Simon et al., 1987). Another approach has been
the isolation of cryptic transformants i.e. normal cell clones
which fail to respond to the oncogenic influence of viral
transforming genes (Ryan et al., 1985). Some investigators have
looked for cellular proteins which bind directly to viral
oncoproteins (Harlow et al., 1986, Yee and Branton, 1985) and
have attempted the isolation of transformation revertants which
descended froiti a transfoinned cell and lack at least one of the
transformation properties. This approach has been used in the
présent study and is described below.
2. Reversion of transformation
Cells in the transformed state are defined by certain
characteristics such as changes in altered growth and morphology,
acquired anchorage independence, ability to grow in semi-solid
média and to produce tumors when injected into animais. Very
little is known about the mechanism(s) by which the transforming
agents alter essentiel cell metabolism required to maintain the
"normal" cellular growth state. One way of investigating the
altérations between the transformed state and the normal state is
to isolate from a culture of malignant cells, flat revertant
cells that lack at least one of the properties of a transformed
cell from which it is descended (Vogel and Pollack, 1974).
This promising approach can be used most successfully in
characterizing cellular genes that are involved in preventing or
antagonizing cellular transformation i.e. selecting cells capable
of suppressing the transforming activity of a defined oncogene.
This genetic approach was accomplished in the past by cloning
rare flat revertants arising during culture or by selecting cells
surviving cytotoxic drug treatment under conditions favoring the
growth of transformed cells (Bauer et al., 1987; Noda et al.,
1983; Norton et al., 1984; Ryan et al., 1985; Samid et al., 1987;
Stephenson et al., 1973; Vogel and Pollack, 1974; Talbot et al.,
1988) or by using a fluorescence activated sorting technique
(Haynes and Dowing, 1988; Zarbl et al., 1987). Some of the above
mentioned procédures resulted in three classes of flat revertants
isolated and characterized from cells transformed by spécifie
oncogenes. The first class of revertants resulted from
inactivation of the spécifie oncogenes (Cho et al., 1976;
Fischinger et al., 1972; Greenberger and Aaronson, 1974; Mathey-
Prevot et al., 1984; Maruyama et al., 1981; Ozanne and Vogel,
1974; Varmus et al., 1981; Vogel and Pollack, 1974; Wilson et
al., 1986). Those in the second class were due to inactivation
of cellular target genes (Inoue et al., 1983; 1989; Norton et
al., 1984; Ryan et al., 1985; Sacks et al., 1979; Stephenson et
al., 1973; Talbot et al., 1988; Zarbl et al., 1987), or co-
operating genes (Katz and Carter, 1986) required for
transformation by a spécifie oncogene. The third type of
revertants resulted from activation of dominant transformation
suppressor genes (Noda et al., 1983; Kuzumaki et al., 1989). Of
the three classes only the second or third class revertants are
of great value for elucidating the mechanism(s) or the existence
of common pathways of cellular transformation (Bassin and Noda,
1987) as they are target-related, résistant to retransformation
and continue to express the transforming protein(s). These cells,
phenotypically normal or quasi-normal, are expected to contain
the mutations in either the cellular target gene(s) in question
or in oncogene suppressor gene(s).
STUDIES WITH ADENOVIRUSES
Biochemical studies with cells transformed by oncogenic
viruses has extended our basic knowledge of cell growth
régulation and tumorigenesis. Since the discovery that certain
species of adenovirus were oncogenic when injected into newborn
hamsters and rats (Huebener et al. 1962; Trentin et al. 1962) much
knowledge has accumulated about the structure and expression of
adenovirus transforming genes. Adenoviruses are viruses of human
origin and are known to be disseminated in the human population,
particularly in young children, causing gastroenteritis, a wide
variety of respiratory illness and frequently latent infections
(Israël, 1962; Yabe, 1964; Rosen, 1960). Although, it is
extremely unlikely that human adenoviruses are causâtive agents
of cancer in man, they have the ability to transform cells and,
as a resuit, are considered to be powerful tools to study
mammalian cell transformation. In addition to delineating the
process of transformation of normally growing cells to tumor
cells, the adenoviruses were extensively used as model Systems to
study the organization and expression of eukaryotic genes. Many
properties unique to eukaryotic organisme were in fact observed
during studies with DNA viruses. Thus adenoviruses provided an
excellent expérimental system to investigate the molecular
biology of mammalian- cells in général, including cell
transformation and régulation of gene expression.
1. Cells transformed bv adenoviruses
Cells which are semipermissive or nonperinissive to the
adenovirus infection are transformed by the virus. Segments of
adenoviruses were shown to integrate into the genome of
susceptible cells, and cells which contained the transforming ElA
and ElB genes from the left of the viral DNA (Gallimore et al.
1974, Sambrook et al. 1975) or the whole viral genome (Green et
al., 1976) were transformed. Independent cell lines transformed
by human adenovirus type 2 (Ad2) possess the left-hand end of the
viral DNA and in some cases only 14% of the total Ad2 DNA was
integrated into the cellular genome. Very often multiple partial
copies of viral DNA not colinear with the viral genome were found
integrated into the genome of the transformed cell (e.g. the
adenovirus 2 genome in F4 cells used in the présent study (see
Fig. 1)).
2. The adenovirus genome
Genetic information of the adenoviruses is coded by a double-
stranded linear DNA (molecular weight 2.0-2.4 x lO^daltons; van
der Eb and van Kestern, 1966; Green et al., 1967), and the genome
can be divided into two functional domains (Fig. 2). The first
domain consista of four groups of "early" genes that are
expressed during the early phase of the infection and products
derived from this phase are required for activation of the larger
set of "late" genes that comprise the second domain (Berk, 1986;
Flint, 1977). The early phase of an adenovirus infection is
initiated by expression of the pre-early transcription unit ElA
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FIGURE Ij. Map of the Ad2 genome integrated in F4 cells (Tooze,
1981).
The upper diagram shows the structure of a tandem
array of viral and host sequences found in the Ad2
transformed rat embryo cell line, F4. The lower
diagram is the enlargement of one of the viral and
cellular sequence. Viral DNA sequences are
represented by the block areas, the flanking
cellular sequences are shown as thin lines. (Taken
from Tooze, p 576 d).
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FIGURE 2 ; Map of the Ad2 genome with two functional domains
(Early and Late) (Flint, 1977) .
The DNA duplex is represented by the horizontal
line (0-100 units). Thick arrows represent the
direction of transcription of the major early
domains numbered ElA to E4.
The narrow arrows correspond to the late units
specifying the late promoters i.e. IX and IV a2,
included in this unit are the transcripts
starting at the major late promoter (MLP) .
Nevins, 1981) . In addition, the ElA and ElB genes, both early
phase transcription units of adenoviruses, are together
responsible for the oncogenic transformation ascribed to
adenoviruses (Graham, 1984). Both ElA and ElB genes are found in
the transforming région called El.
3. The transforming région El
This région is located in the first transcription unit of
the adenovirus DNA (r-stand) and can be divided into two régions,
ElA and ElB (Wilson et al. 1979; Berk and Sharp, 1979). The
organization of this région of the genome is very similar among
varions adenovirus serotypes (Ad2, Ad5, Ad7 and Adl2) (Grand,
1987) . These genes are the first set to be transcribed and
expressed after the onset of virus infection and rely completely
on the host cell transcription and translation mechanism.
(a) ElA région
The ElA région (map units [m.u.] 1.3 to 4.5 in the adenovirus
serotype 2 and 5) codes for two proteins 289R and 243R. These
proteins have identical amino and carboxy termini but differ in
their internai primary sequences as a resuit of differential RNA
splicing (Berk and Sharp, 1978; Chow et al. 1979; Perricaudet et
al. 1979). Each of the primary translation products undergoes
extensive posttranslatipnal modification resulting in a sériés of
highly related proteins that are located in the nucleus of • the
cell (Harlow et al. 1985). Although both 289R and 243R species
are required for cell transformation (Branton et al. 1985), the
289R product alone was shown to stimulate (Kingston et al. 1985;
Liu et al. 1985) or repress (Borrelli et al. 1984; Hen et al.
1985; Velcich and Ziff, 1985) other viral or cellular genes (Siva
Raman et al. 1986; Nevins, 1982; Kao and Nevins, 1983) and
trigger synthesis of cellular DNA (Oda et al. 1986; Stabel et al.
1985; Branton et al. 1985).
Comparison of ElA proteins among adenovirus serotypes
revealed a pattern of highly conserved régions alternating with
sequences of low hoitiology (Kiitunelman et al., 1985; Figge et al.,
1988) . The three conserved sequences were 'designated as régions
1, 2 and 3 (Moran and Mathews, 1987) . Results from coitibined
mutational analyses revealed the three régions to be functional
domains of the ElA proteins (Fig. 3). Domains 1 and 2, common to
both the 289R and 243R polypeptides, appear to be required for
immortalization, collaboration with ras in transformation and
induction of cellular DNA synthesis (Lillie et al. 1986; Moran et
al. 1986; Lillie et al. 1987; Zerler et al. 1986; Schneider et
al. 1987; Subramanian et al. 1988; Whyte et al. 1988b). Domain
3, which is spécifie for the 289R polypeptide, can efficiently
transactivate early viral and cellular genes (Carlock and Jones,
1981; Montell et al. 1982 ; Moran et al. 1986; Glenn and
Ricciardi, 1985; Lillie et al. 1986; 1987) , but it is not
required for cell transformation and immortalization (Whyte et
al. 1988b; Green, 1989). From mutational analysis of the ElA
protein coding région it was apparent that some activities of ElA
were distinct from others and were carried out independently by
différent régions of the protein. These observations indicated
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FIGURE 3 ; The functional domains of the ElA proteins (Moran and
Mathews, 1987).
The three conserved domains 1, 2 and 3 were
revealed by mutational analysis. Messenger RNAs
of the major ElA Ad2 are shown as lines with
arrows for direction of transcription and the
caret symbols to indicate introns. The protein
coding régions are indicated as boxes on the
mRNAs. Each filled box labeled 1,2 and 3 in the
ElA protein refers to the highly conserved régions
(Lillie et al., 1986, Moran et al., 1986, Zerler
et al., 1987). The number of amino acid residues
(R) in each protein is shown as are the
sédimentation coefficients of the ElA mRNAs. The
function of each domain is mentioned in the text.
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ElA proteins are multifunctional proteins at the biochemical
level (Moran and Mathews, 1987).
Since the ElA protein is not a DNA binding protein (Ferguson
et al. 1985), cellular activation mediated by this protein was
suggested to be an indirect event involving host cell coinponents
(Feldman et al 1982; Impériale et al. 1983; 1984; Nevins et al.
1988). Recently the interaction between ElA and a sériés of
cellular polypeptides, the most abundant of which are 300, 107
and 105 Kd (Yee and Branton, 1985; Harlow et al. 1986) was
detected by coimmunoprecipitation. The 105Kd polypeptide was
identified as a product of the cellular retinoblastoma (RB) gene
(Whyte et al. 1988a). Recently, Whyte et al.(1989) used a
variety of ElA mutants and showed the binding site of pl05, the
RB protein, required both conserved régions 1 and 2 of ElA which
were previously believed to be involved in transformation.
However, the other two cellular proteins bind in an overlapping
fashion to the same ElA régions as the pl05-RB with the 3 00Kd
polypeptide binding to région 1 and the 107Kd polypeptide to
région 2 (Whyte et al. 1989). Although there are différences in
the précisé binding sites of these three proteins, this study
suggested that the cellular polypeptides were potentiel targets
for the ElA transforming function(s).
Several oncogenes, including the polyoma large T antigen
gene, members of the mvc gene family or the p53 oncogene were
shown to replace ElA for transformation of the cell (Land et al.
1983; Ruley, 1983; Eliyahu et al. 1984; Jenkin et al. 1984;
Parada et al. 1984; Schwab et al. 1985; Yancopoulous et al. 1985)
and vice versa (Zerler et. al., 1986). ElA by itself is not
12
sufficient for complété cellular transformation. The ElB région
is required for complété transformation (Houweling et al. 1980;
van den Elsen et al. 1983a).
(b) ElB région
The ElB région (map unit 4.6 to 11.2) codes predominantly
for two proteins, (55Kd and 19Kd) both in infected and
transformed cells (Stillman, 1986). In transformed cells, both
products are translated from the same 22S mRNA, but from
différent reading frames and therefore do not have common amino
acid sequences (Bos et al. 1981; Branton et al. 1985) . The
19Kd protein can also be translated from the 13S mRNA in infected
permissive cells, during late infection. Other minor proteins,
related to the 55Kd protein, with unknown functions were also
identified, but are derived from a third existing ElB mRNA
(Anderson et al. 1984; Virtanen et al. 1982; 1985). In addition
to these the ElB DNA was shown to encode another spécifie
structural protein, pIX, (Wilson et al. 1979; Alestrom et al.
1980) which is transcribed from an indépendant promoter.
The ElB région itself, has no transforming capacity, but
contributes to cell transformation in severval ways (van den
Elsen et al. 1983a). The ElB sequences are required for complété
expression of the transformed phenotype, since cell lines
transformed only with the ElA DNA were observed to be ^ incomplète
transformants' due to a fibroblastic appearance. These cells
showed différences in growth patterns and tumorigenicity
(Houweling et al. 1980; Gallimore et al. 1985b) in comparison to
13
cells containing the entire El région. Jochemsen et al. (1987)
found that the ElB région was required in the cis position for
enchanceinent of the transcription-initiation rate of the ElA
région and complété oncogenic transformation of cells.
At least five functions, derived from characterization of
adenovirus mutants, were assigned to the ElB proteins (Barker and
Berk, 1987; Grand, 1987; Flint 1987). Both the major products are
required for complété transformation of cells in culture
(Bernards et al 1986). The larger ElB protein (Ad 55Kd) can
complex with the E4(25Kd) protein (Flint, 1987; Grand, 1987) and
inhibit host-cell protein synthesis by interfering with the
transport of the cellular RNA from the nucleus to the cytoplasm
(Babiss and Ginsberg, 1984; Babiss et al. 1985; Pilder et al.
1986). The smaller ElB protein (19Kd) protects both viral and
cellular DNA from dégradation during the course of infection and
régulâtes viral participation (White et al. 1984a, 1984b; 1986;
1988; Lai Fatt and Mak, 1982; Pilder et al. 1984; Subramanian et
al 1984) in cellular gene expression and transformation (Herbst
et al. 1988).
A potentially interesting property of the large ElB protein
is its association in transformed, but not productively-infected,
cells with a cellular récessive, antioncogenic, (Hinds et al.,
1989) tumor protein, p53 (Sarnow et al. 1982), which also binds
to the SV40 large T antigen (Crawford, 1983). However, it is
not clear whether the ElB-p53 complex per se has a rôle in cell
transformation.
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4. Transformation revertants selected with drugs
As mentioned earlier, in the reversion of transformation
section, the goal of isolating transformation revertants is to
understand the mechanism(s) of malignant cell transformation
(Ozer and Jha, 1977; Bassin and Noda, 1987). By using spécial
techniques such as négative sélection which involves placing a
population of transformed cells in a situation which supports the
growth of only transformed cells and adding an agent which is
toxic and preferentially kills transformed cells, flat revertants
from différent cell lines transformed by différent agents can be
isolated and characterized to define and résolve the above
mechanism(s). Recently, revertants have been isolated by
positive sélection i.e. on the basis of their résistance to
certain drugs (Noda et al., 1983). There are some advantages to
the isolation of such drug-resistant mutants. Drug résistant
mutants frequently have other properties which allow the
investigator to begin the genetic analysis of a system which
would otherwise be very complicated. The drug-resistant mutants
in the example given above are sometimes defective for
transformation, continue to express the transforming proteins and
are phenotypically normal. A combination of these properties was
found useful for the isolation of transformation revertants
(Bassin and Noda, 1984; Klein, 1988).
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DRUG RESISTANCE
Development of drug-resistance is one of the major causes
for failure of chemotherapy in cancer patients and this area is
under investigation in several laboratories (Ling et al., 1988;
see réf. in Gupta, 1989). Studies with drug résistant mutants
should prove useful in understanding the molecular mechanisms of
drug action, .eventually leading to a more effective
chemotherapeutic usage of drugs.
This study is concerned with characterization of the
methylglyoxal-bis(guanylhydrazone)-résistant detransformed
mutants (MGBG^) isolated from adenovirus transformed rat cells.
1. METHYLGLYOXAL-BIS(GUANYLHYDRAZONE^ (MGBG^
Methylglyoxal-bis(guanylhydrazone) (MGBG) is a drug used to
treat cancer patients and was first reported by Freedlander and
French (1958) to inhibit the growth of leukemia cells in mice.
Later, French et al., (1960) postulated MGBG resembled spermidine
structurally (Fig. 4A) and thus probably interfered with the
biological function of the naturally occurring polyamines. In
1972, Williams-Ashman and Schenone discovered that MGBG was a
powerful inhibitor of s-adenosylmethionine decarboxylase (EC
4.1.1.50), the second rate limiting enzyme in polyamine
metabolism.
(a) Structure-activitv relations of MGBG
The MGBG molecule contains several différent domains (Fig.4B)
responsible for its varions activities (Janne et al., 1985).
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FIGURE 4: Chemical structures of spermidine and
methylgloxal-bis(guanylhydrazone) MGBG
(A) Spermidine structure.
(B) MGBG structure. The domains A, B, C and D
represent various activities assigned to the MGBG
molecule (Janne et al., 1985). Domain A, formed
by Carbon number 4 and groups attached to it,
influences inhibition of s-adenosylmethionine
decarboxylase. Domain B constitutes the entire
length of the molecule and is utilized for binding
to the polyamine carrier transport. Domain C and
D are amino-guanidine derivatives responsible for
the inhibition of diamine oxidase (Janne et al.,
1985).
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There are four domains, namely A, B, C and D. Domain A, formed
by the central carbon and ail groups attached to it, influences
inhibition of the s-adenosylmethionine decarboxylase. The entire
length of the molecule constitutes domain B and is utilised for
binding to the polyamine carrier. The exterior portions of the
molecule (domains C and D) are responsible for diamine oxidase
(EC 1.4.3.6) inhibition.
(b) Properties and Function of MGBG
Under physiological conditions, due to its positive charge,
MGBG has several intracellular binding sites (Pegg and McCann,
1982, Janne and Morris, 1984), induces enzymes like spermidine N'-
acetyltransferase (SAT) (Persson and Pegg, 1984, Pegg et al.,
1985b, Karvonen and Poso, 1984) and interfères with polyamine
transport (Wiseman et al., 1983, Kramer et al., 1985). In
addition to inhibiting cellular polyamine biosynthesis, MGBG also
damages mitochondria (Mikles-Robertson et al., 1979, Williams-
Asham and Seidenfeld, 1986) . As a resuit there are some
limitations to its clinical usefulness because of its somewhat
nonspecific cytotoxicity (Kingsnorth, 1986).
(c) Cellular uptake of MGBG
Transport of MGBG into the cells occurs by the polyamine
transport system as naturally occuring polyamines due to its
structural resemblance with spermidine and it can influence the
normal cellular flux of polyamine compounds (Dave and Caballes,
1973, Gordensmith et al., 1983, Williams-Ashman and Seidenfeld,
1986). Although MGBG resembles spermidine, it does not undergo
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biotransformation and is often used as a nonmetabolised substrate
for detailed characterization of the polyamine transport system
(Pegg, 1988, Williams-Ashman and Seidenfeld, 1986). Uptake and
accumulation of MGBG was shown to occur both in normal as well as
malignant cells (Kramer et al., 1985). However, under certain
expérimental conditions MGBG accumulated to a greater extent in
cancer tissues than in normal tissues, not necessarily due to
malignancy, but primarily due to rapid multiplication or division
of mice cells (Kallio et al., 1983, Herr et al., 1981).
2. Polvamine biosvnthesis pathwav
The three key enzymes that regulate the mammalian
polyamine biosynthesis pathway are: (1) ornithine decarboxylase
(ODC; EC 4.1.1.17), (2) S-adenosylmethionine decarboxylase
(SAMDC; EC 4.1.1.50) and (3) Spermidine/Spermine N'-
acetyltransferase (SAT; no EC number assigned) (Pegg et al.,
1982, Morgan, 1987).
Ail three enzymes have been targets for analysis of
polyamine synthesis since they are highly regulated, have very
short half lives and are essentially rate-limiting enzymes in
this pathway (Morgan, 1987, Pegg and McCann, 1982, Tabor and
Tabor, 1984, Porter and Sufrin, 1986, Pegg, 1986, 1988).
(a) S-adenosvlmethionine decarboxvlase
Among various enzymes of the polyamine biosynthesis pathway
the SAMDC (the only enzyme studied in this présent study, as it
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is the target component of MGBG) has been most thoroughly
investigated due to its rate limiting rôle in this biosynthetic
pathway. It is a putrescine-activated enzyme and is présent in
minute amounts in normal and malignant cells (Pegg et al., 1981,
Williams-Ashman and Seidenfeld, 1986). The enzyme has a subunit
Mr of 32,000 and contains a covalently bound pyruvate prosthetic
group (Pegg, 1984a, Tabor and Tabor 1984b). The rôle .of SAMDC is
to provide an aminopropyl donor for the formation of spermidine
and spermine (Pegg and Williams-Ashman, 1969) by decarboxylating
s-adenosylmethionine. Like ail pyridoxal-phosphate-dependent
decarboxylases, the SAMDC reaction proceeds with rétention of
steric configuration of the substrate (Allen and Klinman, 1981).
This enzyme was recently cloned by the cDNA method from rat
prostate, after pretreatment with MGBG to increase tissue content
of the enzyme (Poso and Pegg, 1982, Shirahata and Pegg, 1985,
Pegg et al., 1973,). As such MGBG has no effect on the mRNA
(Pegg et al., 1988) and is able to stabilize the protein (Pegg et
al., 1984a, Pegg, 1984b). In vitro translation showed SAMDC to
be first synthesized as an inactive precusor of Mr 37,000, then
converted to an active form of Mr 32,000 containing the pyruvate
prosthetic group and it can exists as a protein dimer (Pegg,
1986, Pegg et al., 1988). Southern blot analysis of rat, mouse
and human DNA suggests that SAMDC belongs to a multigene family
and its sequence is highly conserved among mammals (Pegg et al.,
1988, Morgan, 1987).
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TUMOR NECROSIS FACTOR
In cancer chemotherapy, clinical studies have shown that
cytokines, e.g. tumor necrosis factor (TNF), provide an
opportunity for advances in antitumor therapy (Frei and Spriggs,
1989). This therapy is potentially superior to most classical
cancer chemotherapeutic agents because of its extremely high
selectivity for tumor cells.
A. Historv of TNF
Several years ago physicians observed rare spontaneous
régression of tumors in cancer patients and this occurrence
coincided occasionally with bacterial infections. Attempts to
recreate this phenomenon failed and the investigation was further
limited by marked toxicity of the préparations used i.e. crude
form of bacterial products (Coley, 1893) or purified form (LPS)
(Shear et al., 1943). Some years later, a factor called tumor
necrosis factor (TNF) was isolated from mice (Carwell et al.,
1975) treated with bacterial lipopolysaccharide (LPS) (Fisch and
Gifford, 1983, Mannel et al., 1980, Matthews, 1981, Satomi et
al., 1981) and shown to exhibit tumor necrosis activity.
B. Isolation and Structure of TNF
TNF originally obtained from LPS-induced monocyte lines,
is now known to be produced by activated lymphocytes (Turner et
al., 1987), a number of tumor cells and various cell lines e.g.
chronic B-cell malignancies and human epithelial cell.
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(Cordingley et al., 1988a, Dealtry et al., 1987). In addition to
LPS, the cell lysate products of several parasites, viral
partiales, and enterotoxin induce TNF expression and release
(Aderka et al., 1986, Hotez et al., 1984, Nedwin et al., 1985,
Wong et al., 1986). In both man and mouse, TNF is encoded by a
single copy gene and is linked to the major histocompatibility
complex (Spies et al., 1986) that has been cloned and sequenced
from HL-60 cells for human TNF and from PU5-1.8 murine macrophage
cells for the murine TNF (Pennica et al., 1984, Marmenout et al.,
1985, Wang et al., 1985). TNF is produced as a pro-hormone with
a well-conserved 76- 79 amino acid N-terminal appendage, the
function of which is unknown (Caput et al., 1986, Pennica et al.,
1984). Although not expressed constitutively, TNF mRNA forms
0.5% of total cellular RNA (Beutler et al., 1986) after
activâtion, however, it is extremely unstable. Recent evidence
suggests that post-transcriptional down régulation of TNF may be
due, in part, to destabilization of the TNF message by a non-
transcribed 3' sequence (Caput al., 1986). The native, mature-
17Kd TNF is a trimer, with each subunit containing a cysteine-
bond and this protein multimer is thought to be the active form
of the complex (Smith and Baglioni, 1987).
Virtually ail somatic cells, with the exception of
erythocytes, possess a receptor for TNF (Kull er al., 1985).
Following binding, the receptors are internalized within minutes
and receptor re-expression may not occur for up to 48h
(Cordingley et al., 1988b). Little is known about the signais
that are transduced after binding of TNF to its receptor,
however, a rapid change in cellular transcription and translation
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results, leading to an altered profile of cellular protein
synthesis, and thus cell function (Balkwill, 1989).
C. Studies on the activities of TNF
TNF is considered to be a pleiotropic cell regulatory
cytokine, which acts on a variety of cells and induces a spectrum
of responses depending on the target cell (Beutler and Cerami,
1988, 1988a, 1988b, Balkwill, 1989, Brenner, 1988, Fiers et al,,
1988, Frei and Spriggs, 1989, Malik and Balkwill, 1988, Old,
1987, 1988, Oliff, 1988, Ruddle, 1987, Tracey et al., 1988). TNF
has the ability to act as a growth factor for some cells
(Sugennan et al., 1985, Vilcek et al., 1986) or as an inducer of
differentiation in others (Jelinek and Lipsky, 1987). TNF is
considered central to induction of the inflammatory response and
it is also an immune modulator which suggests that TNF plays a
modulatory rôle in inflammation and immunity in the mammalian
System (Beulter and Cerami, 1987, Old, 1987).
TNF was originally characterized on the basis of its
activity against tumor cells, while sparing normial cells both in
vitro and in vivo (Carswell et al., 1975, Helson et al., 1975,
Old, 1985, 1988). Some of these properties of TNF are discussed
below.
(1) Cvtotoxic activities
One distinct function of TNF is its ability to reduce tumor
cell survival. Certain tumor cells and tumor cell lines are
directly susceptible to the cytotoxic action of TNF (Carswell et
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al., 1975). These cells are ail TNF receptor positive, although
the nxunber of receptors expressed does net correlate with the
degree of sensitivity (Aggarwal et al., 1985, Kull et al., 1985).
A number of mechanisms were suggested as to why soitie cells are
particularly sensitive to direct killing by TNF, including free
radical génération during TNF dépendent conversion of arachidonic
acid to prostaglandins, intracellular release of lysosomal
enzymes (Ruddle, 1987), free oxygen radical formation (Wong and
Goeddel, 1988) and the inhibition of synthesis of certain
important endogenous proteins (Hahn et al., 1985, Kull and
Cuatrecasas, 1981, Ostrove and Gifford, 1979). Whatever the
mechanism, cell death occurs in association with DNA
fragmentation, well before cell lysis occurs (Dealtry et al.,
1987, Rubin et al., 1988, Ruddle, 1987, Laster et al., 1988,
Schmid et al., 1986, 1987).
(2) Antiviral activitv
TNFs can induce a cellular antiviral state, similar to that
of interferons (Koff and Fann, 1986, Mestan et al., 1986, Wong
and Goeddel, 1986). Together with other cytokines, they protect
cells from infection by both DNA and RNA viruses, though not on a
broad spectrum of cells as do interferons (Balkwill, 1989).
However, a single oncogene product is sufficient to render the
cell susceptible to the cytotoxic action of TNF. Two well known
oncogene products that can induce TNF sensitivity are pp60^~®^°,
a tyrosine protein kinase, and ElA (Fletcher et al., 1987, Chen
et al., 1987, Gooding et al., 1988). Although the latter
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oncogene product is responsible for susceptibility to TNF lysis,
the mechanism for this activity is not known. On the other
hand, pp60^~®^*^ is thought to overcome cell résistance to TNF by
inhibiting the formation of gap junctions (Fletcher et al.,
1987) .
The sélective toxicity of TNF against certain tumor cell
lines and the varions other functions of TNF are apparently
mediated by activating complex(es) and perhaps indépendant
biochemical pathways (Reid et al., 1989) in the cells.
•
RESEARCH OBJECTIVES
The présent study deals principally with investigating the
basis of drug-resistance and the cause of detransformation in
mutants derived from an Ad2 transformed rat cell line (Gallimore,
1974). Further, an attempt has been made to characterize
cellular genes involved in the transformation process. Knowledge
of these parameters is important to establish a possible link
between drug-resistance and detransformation.
(1) To investigate the basis of drug résistance, in these cells,
there are two potentiel possibilities: (a) the cellular target
enzyme, SAM-decarboxylase, has an altered affinity to MGBG or (b)
the cells have an altered drug transport. To assess these
possibilities, an enzymatic assay was performed to investigate
whether the target enzyme incurred a mutation and as a resuit
led to development of résistance or if the résistance was due
mainly to cell surface changes leading to altered drug
transportation.
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(2) For cellular detransformation, there could be three possible
causes: (a) loss or inactivation of the adenovirus transforming
genes (ElA and ElB) , (b) mutation in a cellular gene which is
required for transformation, and (c) activation of a cellular
tumor suppressor gene. To distinguish between these
possibilities, several experiments were designed and carried out
as described briefly below:
(A). Are the El genes functional in the detransformed cell lines?
As we have already reported elsewhere, the integrated
adenovirus oncogenes remained unaltered and continued to
synthesize the ElA and ElB oncoproteins (Rodrigues et al., 1987,
Sircar et al., 1987, Sircar and Weber, 1988) in the detransformed
cells. To prove uneqivocally that the cause of detransformation
was due to a change in the cellular genome, the functional
integrity of El products was tested directly by their capacity
to complément El deletion mutants and also by the El-dependent
lytic effects of tumor necrosis factor-alpha. The results show
that some cell lines express biologically functional ElA proteins
and the ElA protein, itself, is responsible for inducing cell
susceptibility to TNF. However, the mechanism is not known.
(B) . Is the El"^ revertant cell line, G2, defective in a cellular
factor required for El-mediated transformation?
Our findings suggest that the El proteins are functional in
the G2 revertant cell line. This was supported by the studies of
Sircar et al. (1988), demonstrating that this revertant appeared
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to be résistant to retransformation by El plasmids. These
results suggest that the résident El proteins in this cell line
are net altered or affected. Hence a cellular mutation could be
the cause for detransformation, one that perhaps behaves in a
dominant manner. To test this hypothesis, somatic cell hybrids
were constructed between F4 and G2 as well as G2 and FR3T3. The
results suggest that the G2 mutation is dominant and the
revertant phenotype does not resuit from the absence of some
cellular factor neccessary for transformation.
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MATERIALS AMD METHODS
1. CELLS
The F4 cells, derived from embryonic rat brain cells and
transformed with Ad2 (Gallimore et al., 1977), were obtained froiti
Bruce Stillman (Cold Spring Harbor Laboratory). These cells are
shown to have a transformed phenotype by their ability to (a)
grow either in soft agar or in low sérum to high density and (b)
induce tumors in immunosuppressed rats and nude mice (Gallimore
et al., 1977). The cells contain 16 copies of an Ad2 DNA
fragment integrated at a single site (Flint, 1977). The F4
cells were recloned three times in succession and the variants
used in the présent study were isolated from only one of the
subclones (Sircar et al., 1987).
(a) Growth Conditions
Ail cells were grown in Dulbecco's modified Eagle's
essentiel médium (DMEM, GIBCO) containing 5% calf sérum (GIBCO)
in air-5% CO2 incubators at 37° in Falcon plastic 10 cm pétri
dishes.
2. ISOLATION OF MUTANTS
A. Mutaqenesis and Sélection of Mutants
The F4 populations were mutagenized by several
procédures prier to isolation of drug résistant variants
résistant to MGBG. In the présent study several différent
mutagens were used to isolate mutants in order to minimize the
chance of isolating similar mutants. The mutants are called G2,
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G2a, H2, G5, G4, G4F, G4NF, and G4D1. The isolation of these
mutants is described below:
(I) Ethvlmethane sulfonate CEMS) mutaaenesis; The F4 cells
(5 X 10®) were treated with 0.1% EMS (Eastman Kodak, Lot A27) for
4 to 4.5h. The cells were then rinsed with PBS and allowed to
grow for 48h in order to express the point mutations induced by
EMS. Under these conditions, only 50% of the cells survived.
These cells were then used to select mutants in médium containing
15 uM MGBG. Cell lines from this sélection were designated G2
and G1 (Sircar et al., 1987). From the G2 cells, a subclone was
selected and designated G2a.
(II) Retroviral insertion mutaaenesis: The F4 cells (5 x
10®) were infected with the Moloney murine leukemia virus,
ZipNeo-SVX, (Cepko et al., 1984; obtained from B. Roberts,
M.I.T.; 5 X 10^ to 1 X 10® FFU/ml; viral stocks were harvested
from Psi-2 packaging cells), for 3h with occasional agitation.
Twenty-four hours post-infection, cells were treated with 6 uM or
15 uM of MGBG for 2 to 3 weeks. Colonies surviving MGBG-
treatment were isolated and named H2 and G5. These cells were
then further selected for G418 (500 ug/ml; GIBCO) résistance
(Rodrigues et al., 1987).
(III) DNA transfection: For this experiment the F4 cells
were transfected with G2 cellular DNA (10 ug/plate) using the
calcium phosphate précipitation method (Wigler et al., 1979).
Briefly, cells (6 x 10®) in 10 cm pétri dishes were seeded 24h
before transfection. These cells were cotransfected in a 1:10
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ratio with the plasmid pSV2gpt and G2 DNA. Four hours later
cells were shocked with 10% glycerol and incubated at 37°C for
48h, prior to sélection. Mutants were selected from these cells
with 7.5 uM MGBG and designated G4 (Rodrigues et al., 1987).
Subclones G4F and G4NF were derived from the G4 cells. These
clones were isolated according to their cellular morphology. G4F
appeared flat and grew very slowly whereas G4NF appeared very
similar to F4 (epithelial-like). G4D1, another subclone of G4
was isolated after transfecting with an Ad2-E1A DNA bearing
plasmid, pLB206.
(IV) Retransformation ; Some of the above isolated mutants
were retransformed in order to assess if these cells expressed a
biologically functional adenoviral early protein (ElA). The
cells were treated for 48h with freshly prepared 3.0 uM 5-AzaC
(Sigma) or 3.0 uM 6-AzaC (ICN Biochemical). After the cells were
subcultured in absence of the drug, they were checked for
phenotypic altérations. Foci that appeared were picked and
expanded into mass cultures and checked for retransformation.
3. MGBG RESISTANCE
The isolated mutants were selected in the presence of MGBG
in order to isolate mutants with a nontransformed phenotype.
After allowing time for expression and fixation of mutant
phenotypes, cells from each mutagenized dish were replated at a
lower concentration (10^-10^ cells/dish). The following day
varions concentrations of MGBG were added to each dish and the
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médium was changed with fresh médium every third day. After 2 to
3 weeks, colonies which appeared to be résistant to MGBG were
picked and expanded into mass cultures and tested for MGBG
résistance. Growth curves were determined by plating différent
concentrations of cells and MGBG in 10-cm pétri dishes. After 14
to 21 days, the dished were washed with PBS, rinsed with methanol
and the colonies were stained with Giemsa solution (1:10 in
methanol) and counted.
4. PROPERTIES OF THE TRANSFORMATION MUTANT CELLS
In order to assess properties of the isolated MGBG résistant
mutants, several of the transformation properties were examined.
(I) Growth in soft-aaar: Anchorage-independent growth of
the cells was determined by seeding 5 x 10^ cells/60 mm dish in
0.33% agar (Difco) and DMEM supplemented with 10% fetal calf
sérum (GIBCO). Colonies, visible by eye, were counted after 14
to 21 days with the aid of a microscope.
(II) Tumorigenicitv: Balb/c nu/nu mice were used for
these studies to détermine the tumorigenic potentiel of the
varions cell lines. About 5 x 10^ cells per site (in 0.2 ml
DMEM) were injected subcutaneously at three différent places on
the back of each mouse. The mice were observed for up to 16
weeks, noting the day of appearance and growth of the tumors.
(III) Karvotvpe analvsis: Subconfluent cultures (50-60%
confluent) were treated with colchicine (0.6 ug/ml; Sigma) for
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4h. After trypsinizing and gently pelleting the cells they were
placed in an hypotonie KCl (0.75 M) solution for 15 to 50 min at
37°C. These cells were then fixed with methanol:acetic acid
(3:1) for 10 min on ice. Fixation was repeated three times, and
the cells were spread on cold, wet slides and allowed to air dry.
When dried, they were stained with a Giemsa solution (1:10),
mounted in Permount and examined under the microscope.
(IV) SAM Decarboxvlase activitv: This assay was based on
measurements of released from (^^C) s-adenosylmethionine by
cell extracts as described by Williams-Ashman and Schenone
(1972) .
1. Préparation of cell extracts
£
Cells (10°) were washed twice with PBS, harvested in Tris
buffer (Tris 10 mM pH 8.1, NaCl 50 uM, EDTA 1 iiiM) sonicated for
3 0 sec and centrifuged at 10,000 x g for 2 0 min. Supernatant
(0.1 ml) obtained from the above spin was used for the enzyme
assay.
2. Enzyme assav
The reaction was carried out in 2.0 ml Eppendorf tubes each
containing a second modified 500 ul Eppendorf tube with 200 ul
hyamine hydroxide to trap (^^003) released from 2.5 nM (^^C) SAM
in the presence of 100 mM sodium phosphate, pH 7.2, 2.5 mM
putrescine, 5 mM dithiothreitol, various concentrations of MGBG
and the enzyme extract (0.1 ml) prepared above. Ail incubations
were performed at 37°C for 45 min. To terminate the reaction,
0.2 ml 5 N H2SO4 was added to the reaction mixture. The tube was
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then incubated for an additional 30 min at 37°C. During this
period ail the ^^C02 so released was absorbed by hyamine
hydroxide. Total counts in hyamine hydroxide were determined by
counting in aquasol scintillation fluid. Enzyme activity was
expressed as pmoles CO2 released per mg of protein. Protein was
determined using the Bio-rad assay (Bio-Rad Laboratories).
(V) X ^ ^£1 MGBG uptake and efflux studies
(^^C)-MGBG uptake studies were performed with cells grown in
monolayers as described elsewhere (Wiseman et al., 1983). For
these experiments, 5 x 10^ cells were plated in a 6-well (3.5 cm
diameter) Linbro dish in 5 ml DMEM containing 10% calf sérum. At
subconfluence, the médium was replaced with 1 ml fresh DMEM
containing (^^C)-MGBG (19 uCi/umol; Amersham) at a final
concentration of 20 uM. After 1 to 60 min incubation at 37°C the
cells were rinsed three times with cold 200 uM MGBG in PBS, lysed
with 1 ml 1 N NaOH at 60°C for 40 min. Aliquots were taken from
the lysate for protein détermination by the Bio-rad assay and
scintillation counting. Results are based on three expriments,
each carried out in triplicate.
MGBG efflux was measured in 6-cm pétri dishes with the same
concentration of cells as above. The cells were incubated for 30
min at 37°C in the presence of 1 ml 10 uM (^'^C)-MGBG. Rinsed
four times with PBS containing cold 200 uM MGBG, replenished with
3 ml drug-free médium and incubated for various periods of time.
At designated times intracellular MGBG was measured as given
above.
Spermidine uptake was measured in 24-well Linbro plates
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containing 10^ cells/well (Mandell and Flintoff, 1978). Cells
were washed with PBS and incubated with 0.48 ml/well DMEM plus 5%
dialyzed horse sérum (because it is devoid of polyamine oxidase
activity; the sérum was dialyzed against PBS for 16 to 18 h at
4°C). After one hour 20 ul of (^H)-spermidine (40.1 Ci/mmol; New
England Nuclear, 1 uM final concentration) was added and the
incubation was carried on for another 30 min. The cells were
washed, lysed and incorporated radioactivity was counted as
above. Cells grown in parrallel were trypsinized and used for
détermination of cell number.
5. FUNCTIONAL INTEGRITY OF THE ElA PROTEINS
To assess the functional integrity of ElA in transformation-
mutants that express this protein, a deletion mutant dl312 virus
(Jones and Shenk, 1979) was used to détermine whether the
résident ElA compléments the mutant virus for replication in
these cells. The multiplication of mutant viral DNA was
determined by a simple gel technique as described by Gardella et
al. (1984).
(a) Virus
Adenovirus type 2 (Ad2) was used as the probe to detect
viral replication and the Ad5 host-range deletion mutant (dl312)
defective in transformation and replication (described by Jones
and Shenk, 1979) was used for the complémentation assay.
(b) Virus infection
Viral stocks of the Ad 5 host range deletion mutants (dl312)
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were appropriately diluted in growth médium (DMEM supplemented
with 2% calf sérum, and 0.4 mM arginine), and dispersed on F4 and
the revertant cell monolayers. The multiplicity of infection
(MOI) was maintained at 10 PFU/cell. Adsorption was allowed for
Ih at 37°C with fréquent agitation to enhance uniform
distribution of virus over the cells. After adsorption, the
monolayers were rinsed with PBS and incubated with complété DMEM
plus 5% calf sérum for 72 h. The cytopathic effects (cells
rounded up and were grouped together) were évident only in cells
capable of propagating the virus.
(c) Préparation of samples
Samples were prepared for electrophoresis as follows:
Infected cells (between 1 to 2.5 x 10^) were rinsed with PBS,
trypsinized and centrifuged at 10,000 x g for 5 min. The pellet
was resuspended in 0.1 ml sample buffer (15% Ficoll, 2 Kunitz
units RNase type lA (Sigma) per ml, and 0.01% bromophenol blue)
in TBE (0.09 M Tris, 0.09 M Boric acid and 2.5 mM EDTA, pH 8.2)
before electrophoresis.
(d) Horizontal Ivsinq agar gel'electrophoresis
This method was done essentially as described by Gardella et
al. (1984) . The horizontal gels were prepared in two steps.
Initially, agarose (0.75%) in TBE buffer was poured onto a
plastic plate (20 x 25 cm) . Gels were usually 7 to 8 mm thick.
After the gel solidified, wells were eut out 5 cm from the top
(long side) of the gel. A comb was placed in the resulting gap
between the plastic mold and solidified agarose. The gap was
filled with 0.8% agarose in TBE containing 2% SDS and pronase
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(final concentration, 1 mg/ml). After solidification, the gel
was transferred into the gel running tank. The wells were loaded
with cell suspensions in 15% Ficoll and electrophoresed (3h at
0.8 V/cm) at 4°C, immediately, to avoid SDS diffusion and to
allow the cells to be digested. Electrophoresis current was
increased (4.5 V/cm) and terminated when the tracking dye ran out
of the gel completely. The gels were soaked in ethidium bromide
(0.5 ug/ml) for 30 min, visualized and photographed under UV
light.
(e) Southern blotting analvsis
Replicated viral DNA was analyzed by the technique of
Southern (1975) with some modifications. The DNA in the gel was
partially depurinated (15 min in 0.25 M HCl) , then denatured in
0.5 M NaOH, 0.6 M NaCl and 0.015 M sodium citrate. As the DNA of
interest had a large size, the gels were blotted overnight to
allow complété transfer. After blotting the transferred DNA was
crosslinked to the nylon membrane (Amersham) under UV light for 5
min and baked in an oven at 80°C for 2h as suggested by the
manufacturer.
(f) Préparation of probes
Varions DNA probes used in this study were labeled according
to the procédure described in the Multiprime DNA Labeling Kit
(Amersham) . The 50 ul reactions contained 25 ng of heat-
denatured DNA (100°C for 5 min, then chilled on ice for 1 min),
50 uCi of dCTP (^^P; 3000 Ci/mmol ; Amersham), 10 ul of the
multiprime buffer solution (dATP, dGTP and dTTP in a concentrated
buffer solution of Tris-HCl pH 7.8, MgCl2 and 2-mercaptoethanol),
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5 ul of the primer solution (random hexanucleotides in an aqueous
solution of nuclease-free BSA). After the addition of 2 units of
DNA polymerase I^Klenow' fragment (cloned), the mixture was
incubated at 37°C for 30 min (rapid protocol). Probes prepared
•  • • • Q
by this method generally yield a spécifie activity of ~2 x 10
dpm/ug (Amersham). The spécifie activity obtained ~1 x 10^
dpm/ug.
(g) Conditions of prehvbridization and hvbridization of blots
Prehybridization of the nylon membrane was performed
overnight at 42°C in buffer containing 5X Denhardt's solution
(0.2% Ficoll, 0.2% polyvinylpyrolidone, 0.2% BSA; Denhardt,
1966), 5X SSC, 0.1 M sodium phosphate (pH7.0), 50% formamide,
0.1% SDS, 1% glycine and 0.25 mg/ml denatured calf thymus DNA.
The prehybridization solution was replaced with the hybridization
buffer containing 50% formamide, IX Denhardt's solution, 10%
dextran sulfate, 5X SSC, 0.1% SDS, 0.25 M sodium phosphate (pH
7.0), 0.1 mg/ml denatured calf thymus DNA,and the denatured ^^p-
labeled DNA probe. Hybridization was performed for 16h at 42°C.
To remove adhering radioactivity each nylon membrane was
washed twice in IX SSC, 0.1% SDS for 15 min at room température
and the stringent washings were done twice in O.IX SSC, 0.1% SDS
for Ih at 65°C. The filters were air-dried and exposed to Kodak
XAR-5 film for 12 to 24h at -70°C using an intensifying screen.
6. TUMOR NECROSIS FACTOR CYTOTOXICITY ASSAY
The assay was done essentially as described by Chen et al.
(1987). About 2 X 10^ cells were seeded into each well of a 96-
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well Linbro plate 24h prior to addition of human recoitibinant
tumor necrosis factor (rTNF-alpha, Amersham). The cells were
treated with différent concentrations of rTNF for 72h or for
varions time periods with 1 ug/ml rTNF. After the incubation
depending on the requirements, cells were either stained with
0.5% methylene blue or prepared for in situ hybridization to
cellular RNA.
(a) In situ RNA dot blots
RNA was probed according to the in situ hybridization method
of Paeratakul et al. (1988). Briefly, cells were trypsinized and
adjusted to 1 x 10® cells per ml in PBS. Several dilutions in
0.1 ml aliquots were applied to nitrocellulose filter paper using
a  96-well manifold filteration apparatus (BRL) and fixed with
phosphate buffer-1% glutaraldehyde containing 3% NaCl. The
filters were washed in proteolytic buffer (50 mM EDTA and 0.1 M
Tris-HCl, pH8.0) and the cells were digested in the same buffer
containing 20 ug/ml proteinase K (Boehringer-Mannheim).
Hybridization of the filters with appropriate probes was done
according to Maniatis et al. (1982).
(b) Probes
Probes were prepared essentially as for Southern blots given
above.
(c) Prehvbridization and hybridization conditions
Prehybridization of the dot blot filter was essentially
performed as described by Paeratakul et al. (1988). The filter
was prehybridized for 3h at 65°C in 3X SSC, 35% Formamide, IX
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Denhardt's solution, 0.5% SDS, 100 ug sonicated calf thymus DNA
per ml. Then the filter was hybridized with the denatured probe
in the same prehybridization buffer for 16h. The filter was
washed sequentially at room température with 2X SSC, 0.5% SDS for
15 min and O.IX SSC, 0.5% SDS at 55°C. The filter was air-dried
and autoradiographed at -70°C with an intensifying screen.
7. DOMINANCE TEST OF THE CELLULAR MUTATION IN REVERTANT CELLS BY
SOMATIC HYBRIDIZATION
In order to test the dominance of the revertant phenotype in
the revertant cells, fusion experiments were performed with
polyethylene glycol. The resulting hybrids were isolated after
sélection for dominant drug-resistance markers. Hybrids were
grown in spécial média that do not permit the growth of parental
cells.
(a) Dérivation of parental Neo— and Hvaro— cell lines
The Neo^ or Hygro^ cell lines were established by
transfection of parental cells with the appropriate plasmids,
examples: pSVX (Mulligan and Berg, 1982) for neomycin résistance
and pY3 for hygromycin résistance (Blochlinger and Diggelmann,
1984), using the standard calcium phosphate transfection protocol
(Wigler et al., 1979). Briefly, cells (1 xlO^) were seeded in
60-mm pétri dishes 24h prier to transfection. Ten ug of purified
plasmid DNA without carrier DNA in 2 ml DMEM was added to the
cells for 4h.. The cells were shocked with 10% glycerol for 3 0
sec then replenished with complété médium and left to recover
overnight. The cells were split at a ratio of 1:10 (low
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concentrations 10^-10^) into sélective médium containing 400
ug/ml G418 or 100 ug/ml hygromycin B (Calbiochem) , after 2 to 3
weeks colonies were picked in order to establish cell lines.
Media was changed every five days. G418 or Hygromycin sélection
was discontinued after two passages.
(b) Cell fusion with polvethvlene glvcol
G418-resistant cells and hygromycin B-resistant cells were
fused by polyethylene glycol (PEG) treatment using PEG-1000
(Sigma; Craig and Sager, 1985). Cells (5 x 10^) of each cell
line were seeded into a single 3.5 cm-diameter culture dish, and
24h later, the cells were treated with -50% (w/v) PEG for 30 sec.
Cultures were washed rapidly four times with 5 ml serum-free DMEM
and were fed with nonselective médium. After a 24h recovery
period, cells were subcultured into five 10-cm culture dishes.
Hybrids were then isolated in growth médium that simultaneously
selected for cells carrying both markers (Hygro and Neo). This
médium contained 400 ug/ml G418 (GIBCO) and 100 ug/ml hygromycin
B  (Calbiochem) supplemented with 5% fetal calf sérum. Doubly
résistant clones were individually picked and expanded for
tumorigenicity assay and karyotyping. Control experiments prior
to fusion demonstrated that Neo^-cells were sensitive to médium
containing hygromycin B and Hygro^-cells were sensitive to médium
containing G418.
(c) Tumoriaenicitv assav
The tumorigenic potentiel of cell lines derived from above
sélection was evaluated by injecting cells into athymic (nude)
mice as described above (see section 4, Tumorigenicity).
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(d) Karvotvpina
This procédure was done essentially as described above.
(e) Immunoprecipitation
Celle (80% confluent) were labeled for 2h with 200 uCi/ml
(^^S) methionine in DMEM without methionine. Cells from one
lO-cm pétri dish were scraped into 1 ml RIPA buffer (1% TritonX-
100, 1% sodium desoxycholate, 0.1% SDS, 0.15 M NaCl and 0.01 M
Tris-HCl, pH 7.4), freeze-thawed three times, sonicated for 20
sec (Artec) , and centrifuged for 5 min at 10,000 x g. Twenty ul
of antiserum and 250 ul of a 10% suspension of protein A-
sepharose in RIPA buffer were added to the supernatant and
incubated for 2h at 4°C with continuons shaking. The beads were
centrifuged for 5 min at 10,000 x g, washed three times with RIPA
buffer and resuspended in 50 ul lysis buffer for analysis on 9%
SDS-polyacrylamide gels (Laemmli, 1970).
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RESULTS
Despite extensive efforts, net much is known about the
précisé biochemical mechanisin(s) responsible for the malignantly
transformed cellular phenotype. In order to study this mechanism,
we devised a novel sélection systeiti which yielded drug-resistant
variants with altered transformed cell properties (Sircar et al.,
1987). A well characterized adenovirus transformed cell line of
rat origin (F4, Gallimore et al., 1977) was used for this
investigation. These cells were first mutagenized and then
selected for résistance to MGBG, a cancer chemotherapeutic drug.
The selected cells were not only résistant to the drug, but
compared to the parental cells, exhibited a normal or revertant
phenotype (i.e. a nontransformed phenotype).
1. Isolation of MGBG-resistant variants
A. The G2 cell line
A detailed description of the G2 cell line used in this
investigation is given elsewhere (Sircar et al., 1987). Briefly,
the G2 cell line was derived from EMS-treated AD2-transformed rat
F4 cells (Flint, 1981; Gallimore et al., 1977) by a single-step
sélection for MGBG résistance. This cell line behaves as a
transformation revertant (Rodrigues et al., 1987; Sircar et al.,
1987; 1988; Sircar and Weber, 1988) as determined by several
criteria i.e. it
(1) has a flat, contact inhibited morphology,
(2) grows poorly in soft-agar and does not form
tumors in nude mice,
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(3) expresses more EGF receptors and élaborâtes
low levels of transforming growth factor-alpha
(Sircar and Weber, 1988).
In spite of these altérations, the integrated adenovirus oncogenes
appear to be unchanged and continue to synthesize the ElA and
ElB oncoproteins. Therefore, the G2 cells may have lost
responsiveness to the adenovirus transformation genes due to
acquisition of the MGBG^ phenotype.
B. Sélection of other MGBG-resistant variants
In order to obtain several distinct MGBG^ cells
with altered transformed properties, other variants were isolated
by using différent mutagenic procédures (Table 1) to minimize
chances of isolating similar mutants as before (Sircar et al.,
1987) . The drug sélection protocol was identical to that used
for the isolation of G2 cells (Sircar et al., 1987). In some
cases, point mutations were induced by treatment with EMS whereas
in others putative insertions were induced by DNA-transfection or
infection with a Moloney murine leukemia virus derivative (Cepko
et al., 1984; King et al., 1985). The isolation frequency ranged
from 0.8 to 3 X 10~®. Subclones which arose spontaneously from
the G2 and G4 cell lines were named G2a and G4F (flat),
respectively. Both these cell lines maintained the
transformation revertant phenotype even after several years.
However, the G4F cells have lost the integrated El•genes and the
G2a cells do not express the Ela protein(s). Another cell line,
called G4NF (nonflat), was isolated as a MGBG-resistant
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Table 1. Propertles of MGBG-resistant variants
Ce 11
Line
Mutagen MGBG
concentrât ion
dur ing
sélection (uM)
Isolation
frequency
of variants
■^10
( uM)
Présence
of adenovirus
El genes
Colony
formation
soft-agar
(%)
Tumorigenesi
in nude
mice
F4 - - - 4 + 32 24/27
H2 MMLV 6 3 X 10"^ 10 + 1 6/18
G2 EMS 15 1 X 10"^ 34 + 1 0/30
G4 DNA
transfection
7 . 5 8 X 10"'' 38 + 34 0/30
G5 MMLV 15 2 X 10"^ 52 + 0 . 5 0/33
1 D^o is the drug concentration which reduces colony formation to 10% of normal.
Abréviations: EMS, ethylmethane sulfonate; MMLV, Moloney murine leukemia virus.
spontaneous transformant of G4. This cell line has an F4-like
phenotype.
Résistant cells were selected in varying concentrations of
MGBG ranging from 6 uM to 15 uM. The mutants were stably
résistant to the drug over several générations for at least one
year in absence of the drug, giving reproducible D^q values
(Table 1) . The G2 cells can grow in the presence of 8 uM MGBG,
while the more résistant G4 and G5 cells can grow in
concentrations of up to 30 uM. Karyotype analysis showed that
the variants retained the parental F4 cell chromosome number of
60. Double minute chromosomes, frequently found in drug
résistant cell lines, were not detected in these cells.
2. Biochemical characterization of MGBG-resistant cell lines
Three différent phenomena (operating individually or
simultaneously) are primarily responsible for the development of
drug résistance in somatic cells. On exposure to drugs, the
cells may produce an elevated amount of the target component
(e.g. receptor, enzyme, precursor etc.) or the cellular target may
exhibit altered affinity for the drug (i.e. the target receptor
may have an altered structure resulting in reduced/increased
affinity for the drug) and the cellular influx /efflux of the drug
may be affected. To investigate which of these mechanism(s)
is/are responsible for MGBG résistance of the cells, initially
the SAM decarboxylase activity of the various cell lines was
determined as this enzyme is the target component of MGBG. The
transport of MGBG and spermidine by the différent cell lines was
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also studied as drug-resistant mutants were likely to possess
altered transport Systems.
A. Effect of MGBG on SAM decarboxvlase activitv
The SAM decarboxylase activity of différent cell
Unes was determined (Table 2) in cell extracts as detailed in
the Materials and Methods section. The rat prostate gland
extract, the richest source of enzyme, was used as a positive
control. Ail cell lines, except H2, had a similar enzyme
activity. The H2 cells exhibited only half the SAM decarboxylase
activity compared to either the wild type or the MGBG résistant
cell lines. The enzyme was inhibited to a similar extent by MGBG
in wild type as well as the mutant cell lines (Table 2) . From
these observations, it was concluded that the MGBG résistant cells
did not have an elevated amount of the enzyme and also that the
structure of the enzyme was not altered in any cell line. The
cells were, therefore, investigated for MGBG transport.
B. Transport of MGBG
Since our results indicated that the activity of the
target enzyme was unaltered in the mutants, the transport
mechanism of MGBG was assayed as described in Materials and
Methods. The uptake of inhibitory concentrations (20uM) of MGBG
was linear up to 60 minutes in ail cell lines. However, the MGBG
résistant cells G5, G4 and G2, but not H2, took up the drug at a
much slower rate than the parental F4 cells (Fig. 5) . These
results indicated that the résistant cell lines were altered in
their capacity to transport MGBG. Since MGBG and spermidine are
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Table 2. SAM decarboxylase activity and its inhibition by MGBG
SAM decarboxylase
Source of
Enzyme
Speci f ic
act ivity
(pmol/45 min/mg)
Percentage
res idual
activity in presence of
0.5 uM MGBG
F4 14 33
H2 7
ê
30
G2 12 34
G5 13 49
Rat prostate^ 640 82
The prostate, the richest source of enzyme was included as a
positive control and as a standard of comparison (Wi11iams-Ashman and
Schenone, 1972).
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Figure 5. MGBG uptake
Uptake of MGBG by sensitive (F4) and résistant
derivative cells (G2, H2, G4, G5) . Cells were in-
cubated with 20 uM (^^C) MGBG for 2 to 60 min at 37°C,
washed and intracellular MGBG determined. These data
represent the results obtained in three experiments.
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structurally similar compounds, they share a common transport
System (Alhonen-Hongisto et al., 1985) and résistance to MGBG was
shown to accompany decrease in spermidine uptake (Mandell and
Flintoff, 1978). Spermidine uptake was investigated with the G2,
G4 and G5 cells to détermine whether a similar phenomenon was
operative in these cell lines. Ail résistant cell lines showed
decreased spermidine influx as compared to the wild type F4 cells
(Table 3). These observations confirmed the suggestion that the
cause of drug résistance in these cell lines was due to an
altered uptake of MGBG. In order to détermine in which
direction the drug transport was altered (i.e. influx or efflux)
the efflux of the drug in the différent cell lines was assayed.
The cells were initially pulsed with (^^C) labelled MGBG for 30
min, and subsequently, the drug was chased for 8h. As évident
from Figure 6, ail the MGBG résistant cell lines contained less
intracellular drug compared to the parental F4 cells. Ail cell
lines lost the drug rapidly during the first 2h of chase. The
rate of drug efflux was reduced from 2h to 4h and reached a
steady state thereafter in ail cell lines. At any given time the
intracellular drug concentration was always the highest in F4
cells. The fact that the drug levels were almost constant for
any particular cell line from 4h to 8h suggests that the drug
bound tightly to its intracellular targets and was not released.
The low level of binding in the MGBG^ cell lines was probably due
to reduced uptake of the drug (see Figure 5).
It was concluded that the MGBG résistant cell lines are drug
transport mutants and the cells are insensitive to the drug
mainly due to the decreased uptake of the chemical.
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3Table 3. Uptake of ( H)-spermidine by the MGBG-resistant cells
5
pmol/30 min/ 10 cells
JL J.
Line Exp 1 Exp 2 Exp 3 Exp 4 Mean + S.D.
F4 83 . 2 71. 5 76 . 4 75.2
76 . 6 + 4.9
G2 48.1 43.0 58.9 45.8
49 .0 + 7.0
G4 17.5 21.2 23 . 8 16.1
19.7 + 3 . 5
G5 18.3 18 . 8 17.0 24.5
19.7 + 3 . 3
Ln
O
S.D. = standard déviation.
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Figure 6. MGBG efflux
Efflux of MGBG froiii sensitive and résistant cells.
Cells were incubated with 10 uM (^'^C) MGBG for 30 min,
the isotope removed, and intracellular MGBG determined
after further incubation for 0 to 8 hours. These
data represent the results obtained in two experiments.
51
3 . Transformation-related properties of the MGBG-resistant
variants
The primary aim of this investigation was to isolate
revertants of transformed cells i.e. cells that exhibited a normal
phenotype. The drug résistant variants were tested for
properties observed in transformed cells. Among the varions MGBG-
resistant cell lines isolated, a common property was the
significant loss of one or more transformed properties compared
to the parental F4 cells.
A. Transfoimation properties
The data in Table 1 summarize the results obtained from a
variety of studies. Our results show that acquisition of MGBG
résistance by the cells correlated with the loss of one or both
of two key properties observed in transformed cells: anchorage
indépendant growth as measured by colony formation in soft-agar
and tumorigenesis in nude mice. The H2, G2 and G5 cells f ormed
30 fold fewer and significantly smaller colonies in agar, than
those formed by the parental F4 cells. Interestingly, the G4
cells retained the property of anchorage indépendant growth, but
were not tumorigenic. Dissociation between anchorage indépendant
growth and tumorigenicity is believed to be a rare phenomenon
(Peehl and Stanbridge, 1981, Dodson et al., 1981). It has also
been observed in spontaneous human tumor cells which expressed
the phenotype of tumorigenicity in nude mice but did not grow in
soft-agar (Dodson et al. 1981, Marshal et al., 1977). The
transformed F4 cells formed rapidly growing tumors within 21
days, whereas the H2 cells required 60 or more days for a third
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of the total injections to yield tumors. On the contrary, mice
injected with G2, G4 or G5 cells, remained tixmor-free for at
least 100 days. From these results, it was apparent that
sélection for MGBG résistance was an efficient method to obtain
revertants of transformed cells. Furthermore, the highly
transformed F4 cells had a D^q value of 4 iiM, whereas the
nontra.nsformed revertant cells, G2, G4 and G5, had values
ranging from 34 to 52 uM. However, H2, the only revertant that
formed tumors, had a value of 10 uM, which is only 2 fold more
résistant than F4. These observations suggest that there might
be a corrélation between MGBG résistance and the loss of
tumorigenicity in the revertant cells.
B. Integritv of ElA oncoproteins in the revertant cells
The loss of the transformed phenotype in cells can be due
either to the loss or the inactivation of the adenovirus
transforming genes (El) or gene products. To test this
hypothesis, Southern blot analysis and immunoassays were
performed with these cells and the results (Sircar et al., 1987)
showed no change in the adenovirus sequences or the expression of
the genes. However, although the El proteins are expressed in
the cells, they may not be functional. To verify this,
two assays were performed to test the functional integrity of the
ElA proteins.
1. Complémentation analvsis usina ElA deletion mutants
By using an ElA host-range deletion mutant, dl312, we
assessed if the revertant cells expressing endogenous ElA were
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able to complément the mutant virus for replication in these
cells.. Since rat cells are semipermissive for Ad2 and Ad5
replication (Gallimore, 1974) they do not propagate viruses as
efficiently as permissive cells. The replication of the mutant
DNA was analysed as described in Materials and Methods (section
4) . The infected cells were grown for 72h to allow the mutant
virus to replicate. This time period was determined in
preliminary experiments. The assay 1 h p.i. shows that ail the
cell lines were susceptible to infection by dl312 as each
contained uncoated viral DNA (Fig 7, left panel). Figure 7
(right panel) shows that F4 cells which contain and express ElA
and ElB allow the defective virus to replicate. Among the
revertants tested, only G2 and G4D1 had wild type levels of
dl312 DNA, showing positive complémentation. G4D1 is a subclone
of G4 which was retransformed by exogenous ElA genes introduced
by the plasmid pLB206 (Babiss et al., 1983). From the above
results it was concluded that the G2 cells possess ElA proteins
which are fully functional for virus growth. The other
revertants, G2a, G5 and G4F, however, probably had inactivated or
lost their adenoviral transforming genes.
2. Tumor necrosis factor sensitivitv assav
Tumor necrosis factor-alpha is produced by stimulated
macrophages and has a wide variety of biological effects
including sélective killing of certain tumor cells (Beutler and
Cerami, 1988). This factor was shown to be cytotoxic to cells
transformed by the adenovirus type 2 ElA proteins (Chen et al.,
1987) , and causes mortality especially of those cells which do
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Figure 7. Complémentation analysis of MGBG-resistant variants.
The biological activity of the endogenous ElA proteins
expressed by the F4 derivatives résistant to MGBG were
examined. After 1 h or 72 h postinfection, 2 x 10^
infected cells were subjected to horizontal
lysing gel electrophoresis (Gardell et al., 1984).
The gel was blotted on to a nylon membrane (Amersham)
and hybridized with adenovirus type 2 DNA. The arrow
indicates the position of viral DNA. Lane V contained
32 ng of viral DNA.
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not contain the E3 genes. One of the E3 genes élaborâtes the
14.7Kd protein which was recently shown to counteract the El-
dependent lytic effects of TNF (Gooding et al., 1988). To
confirm that the El positive revertants express functional ElA
•proteins, cells were subjected to treatment with recombinant TNF
as detailed in Materials and Methods. Table 4 and Figure 8 show
that only cell lines expressing ElA, siinilar to the parental F4
cells, are sensitive to TNF cytolysis. This resuit confinns a
previous report showing a corrélation between ElA expression and
susceptibility to TNF-mediated cell lysis (Chen et al., 1987).
However, there appears to be a threshold level of ElA expression
required for TNF cytolysis as some cell lines do express a small
amount of ElA protein after 5-azacytidine treatment and yet are
not susceptible to TNF (see G5 Aza). On the other hand, when the
cells were retransformed by 5-azacytidine and produced tumors,
they still remained insensitive to TNF. This suggests
that retransformation or the tumorigenic phenotype is not
required to bring about cytolysis (see Aza-treated cells. Table
4). Thus, our results in Table 4 established three points; (1)
the transformed or tumorigenic phenotype is not required for TNF
sensitivity as long as ElA is expressed (note G4D1, G2 versus
G2a) , (2) a low level of ElA expression may be sufficient for
tumorigenicity but not sufficient for TNF susceptibility (see G5
aza) and (3) tumorigenicity in the absence of the ElA proteins
was not sufficient to bring about cytolysis (see G2a aza, G4F
aza, and FR3T3 aza). These observations suggest that cellular
transformation per se has no effect on TNF cytolysis.
The mechanism of ElA induction of TNF susceptibility is
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Table 4. TNF sensitivity of transformed and revertant cell lines:
corrélation with ElÀ expression and tumorigenicity.
Cell line ElA gene ElA protein ^ Tumor igenicity
nude mice
-  b f
in Sensitivity
to rTNF
F4 + + + +
G4NF + + + +
G4D1 + + +
G2 + + +
G2a + -
G5 + —
G4F -
- -
-
G2a AZA^ + +
G5 AZA° + + /- +
G4F AZA° -
- + -
FR3T3 _ _
FR3T3 AZA"^ —
— + -
ElA proteins were determined by immunoprecipitation as previously described
(Sircar et al., 1987).
Tumorigenicity in nude mice was tested as previously described (Sircar et
al., 1987).
In vityo cytotoxicity assay was done as described by Chen et al. (1987).
See Materials and Methods section.
Cells treated with 6-azacytidine (see Materials and Methods section).
G4F G5 G2a G4NF G4D1 F4
.irun] n- i-__*-:!^TNF(units)
CcQmmà ' oôOd^'
c^c: o^«^ôo^ /OÔOQO^
6:C^6^6^6^6^ "ôOdoo
0:0:0^00^0^ '<: :: 'a0oo «
0:0:6:6:60: 16
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El A
Figure 8. ElA-dependent TNF cytotoxicity assay.
The functional integrity of the ElA proteins in the
MGBG-resista'nt variants was examined. Cells (2 x lO'^)
were treated with différent concentrations of rTNF
(Amersham) for 72 h, then stained with 0.5% methylene
blue. The absorbance at 540 nm was measured with a
microelisa autoreader (Bio-TEK microplate reader). The
absorbance of duplicate wells without TNF was taken as
100% viable.
+ ElA proteins were assayed by immunoprecipitation as
+
described in the Materials and Methods.
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unknown. In search of a mechanism for the TNF-induced cell lysis
of ElA expressing cells, the following facts were considered: (a)
ElA proteins are expressed on the surfaces of both Ad 5 and Ad 12
transformed cells (Bellgrau et al., 1988), (b) ElA is a myc-like
oncogene (Figge et al., 1988, Zerler et al., 1986,), (c) studies
have shown that growth regulatory genes like mvc and fos are
targets of the post-receptor signais of TNF (Schutze et al.,
1988, Kronke et al., 1987, Yarden and Kimchi, 1986, Kirstein and
Baglioni, 1988) and (d) overexpression of ElA can be toxic to
certain cells (Jochemsen et al., 1987). It is possible,
therefore, that TNF may cause excessive transcription of ElA and
c-myc in F4 cells resulting in cell death. The ElA mRNA and the
c-myc itiRNA were detected by using cDNA probes spécifie for the
13S ElA message (Figure 9) and the c-myc mRNA (Figure 10) ,
respectively. Figure 9 shows that the ElA RNA signal increases
with incubation time (compare Oh with 16h in Figure 9) . This,
however, was merely due to cell division as shown by the
équivalent RNA signal at 16h in the absence of rTNF. Dot blot
analysis for the c-myc RNA indicated no change in c-myc
expression in either the sensitive F4 or insensitive FR3T3 cell
(see Figure 10) . Thus, in this system; TNF does not stimulate
either ElA or c-myc expression and it is also évident that
transcription of ElA and c-myc genes was not affected by TNF
treatment of the cells.
The results from the two assays performed above suggest that
transformation revertants, G2 and G4D1, indeed express fully
functional ElA proteins and these proteins play a rôle in
inducing susceptibility to TNF cytolysis. However, TNF has no
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Figure 9. Effect of rTNF on the expression of ElA.
The transcription of ElA in F4 cells, treated with
1 ug/ml of rTNF for the indicated times, were dot
blotted by the procédure of Paeratakul et al. (1988).
The number of whole cells per dot is essentially the
same (1.25 x lO'^ cells/dot) . FR3T3 cells were used as
an ElA négative control. Untreated cells are shown
(see TNF~).
F4(RNase) consiste of F4 cells digested with 1 mg/ml
RNase (DNase free, Sigma)
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Figure 10 Effect of rTNF on the expression of c-myc.
The transcription . of c-myc in F4 and FR3T3
cells, treated with 1 ug/ml of rTNF for the indicated
times, were dot blotted as described in the legend of
Fig. 9 and in the Materials and Methods section.
Note: Time point 0.5 h for FR3T3 was omitted.
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affect on the ElA or c-myc expression in these cells.
4. Genetic analvsis of the affected cellular aene in the
G2 revertant cells
Since the results above suggested that the cause of
detransformation of one of the variants, G2, was not due to a
functionally impaired viral transforming gene or gene products,
genetic analysis of this MGBG^ cell line was carried out. Loss
of the transformation phenotype observed with the mutant could be
due to a cellular mutation that is dominant. To test this
hypothesis, several somatic cell hybrids were constructed between
the revertant G2 and the normal FR3T3 cells, between the
revertant G2 and the parental transformed F4 cells and betweem
the normal FR3T3 and the transformed F4 cells.
A. Characterization of the revertant phenotvpe bv somatic cell
hvbridization
In order to select somatic cell hybrids from the mixed
populations of cells, the parental cells have to be
counterselected. To accomplish this, dominant selectible drug-
resistance markers were introduced into the parental cells by
DNA-mediated transfection. Thus, the G2 and F4 cells were
rendered both hygromycin and G418 résistant, and the FR3T3 cells
were rendered hygromycin résistant (for détails see Materials and
Methods). The phenotypes of these subclones were checked to make
sure that they maintained the properties of the parental cells.
In order to test the dominance of the revertant phenotype, a
sériés of cell fusions was done between the revertant and
nontransformed FR3T3 or transformed F4 cell line as described in
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Materials and Methods. The resulting cell hybrids were
characterized according to their morphology, chromosome number,
MGBG résistance and tumorigenic potential in nude mice (Table 5).
The data showed that ail cell hybrids isolated were real hybrids
as determined by chromosome analysis (Fig 11 and Table 5) . The
number of chromosomes per hybrid ranged from 112 to 161 for cell
fusions between the G2 revertant and the F4 transformed cells and
from 118 to 126 for fusion between the G2 revertant and the FR3T3
nontranformed cells (Table 5). These numbers are consistent with
the total number of chromosomes of the two parental cells. An
examination of the parental G2 and F4 cells showed the two cell
lines to be morphologically indistinguishable and the hybrids
obtained by fusing these cells did not have an altered morphology
either. However, when the G2 or F4 cells were fused with the
nontransformed FR3T3 cell line, the resulting hybrids displayed a
flat morphology similar to the normal FR3T3 cells.
To compare the tumorigenicity of these hybrids in vivo with
that of the parental cells, they were injected into nude mice.
Hybrids of the parental cell line (F4 x F4) produced tumors
within 3 weeks while hybrids between F4 and FR3T3 produced tumors
after 4-6 weeks. The efficiency of tumor formation was also
somewhat reduced. These results suggest that although the
adenovirus El transformation phenotype is dominant, this
dominance is not complété. The presence of FR3T3 genes appears
to reduce the efficiency of tumor formation. Fusion of revertant
G2 cells to normal FR3T3 cells, however, resulted in
nontumorigenic hybrids. This indicated that the revertant
nontransformed phenotype was not due to the absence of some
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Figure 11. Histogram illustrating chromosome number in the
parental and hybrid cells
The bar graph represents the average chromosome
number of each cell line to verify hybrid forma
tion. Hybrids: FF = F4xF4, FG = F4xG2, 3F =
FR3T3XF4, and 3G = FR3T3xG2. The number above each
bar indicates the average chromosome number ob-
served in ten metaphase spreads of each cell line
plus and minus the standard déviation.
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Table ^  Properties of hybrid cells obtained by fusion of the G2 revertant cell
line with the normal FR3T3 or Ad2-transformed F4 cell Unes.
Clone Chromosome ElA protein Tumor/site MGBG Tumor-free
Number(+/-SD) Sens itivity days
Parent
F4 71(+11) + 24/27* S 21*
G2 73(t 3) + 0/30 R 100*
FR3T3 41(± 1) - 0/12-'- R 84^
Hvbr ids
F4 X F4
II V3 121 (+ 9) + 5/9 S 19
III XVII3 ND ND 5/9 S 25
IV E4 138 (+28) + 3/9 ND 18
F4 X G2
II VIII5 112 (±28) + 0/9 S 86
II VIII2 ND + 0/9 ND 56
II XIII2 131 (±31) + 0/9 ND 56
III 146 (+12) + 0/9 S 91
III I2 161 (+14) + 0/9 S 59
III I3 153 (+25) + 0/9 S 44
III I4 ND ND 0/9 ND 59
III I5 ND + 0/9 S 56
IV C2 127 (+23) + 0/8 S 74
F4 X FR3T3
II I4 106 (+14) + 3/6 S 35
II VI4 122 (+32) + 10/15 S 24
II XV4 101 (+17) + 2/6 S 35
G2 X FR3T3
III 2^ 118 (±8) + 0/9 S 59
III 22 126 (+20) ND 0/9 ND 59
III 24 118 (+26) + 0/9 ND 59
IV B2 ND + 0/6 ND 74
V ND + 0/12 ND 66
Ln
ND= not determined. Hybrid clones resulting from différent experiments were designated
by II, III, IV and V; the désignation indicated name of clone isolated from that
experiment. * = performed earlier (Sircar et al., 1987) S =Sensitive R =Resistant
1  = Personal communication (Weber).
cellular component required for the transfomnation process. When
the revertant G2 cells were fused with the transformed F4 cells,
the resulting hybrids were ail nontumorigenic. This resuit
demonstrated that the revertant phenotype was dominant over the
adenovirus-2 El transformation phenotype, suggesting that the G2
cells express a dominant-tumor suppressor factor.
Since the tumorigenicity phenotype was suppressed in the
hybrids between G2 and FR3T3 and between G2 and F4, it was
necessary to détermine whether the ElA oncogene was expressed in
these cells. Immunoprecipitation analysis, using a monoclonal
antibody which recognizes ElA proteins, demonstrated that ail
hybrids, including the nontumorigenic hybrids: G2 x FR3T3 and G2
X F4, expressed the El proteins at a level similar to the
transformed, parental F4 cells (Fig 12) . Thus, suppression of
the transformed phenotype in these cells was not due to the loss
of expression of the viral genome. Interestingly, these
immunoprecipitation results (Fig 12) show a protein band
migrating at the same position as the retinoblastoma protein,
pl05-RB, a product of the retinoblastoma gene. ElA proteins were
shown to bind with this protein (Whyte et al., 1988) and later it
was reported that the binding occurred at the conserved domains 1
and 2 of both the ElA proteins, 289R and 243R (Whyte et al.,
1989). Examination of Fig. 12 suggests that the ElA-RB protein
complexes were présent in G2, F4, as well as ail the hybrids
which expressed ElA proteins. Therefore the formation of a
complex between the ElA and pl05-RB proteins is not sufficient
for transformation as it is still seen in the G2 transformation-
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revertant cells and the nontumorigenic ElA-positive hybrids.
p
To détermine the dominance or recessivity of the MGBG
phenotype, many of the hybrids were tested for their degree of
résistance to MGBG. As shown in Table 5, ail the hybrids tested
displayed sensitivity to MGBG similar to that of the parental F4
cells. Therefore, the MGBG^ phenotype is récessive.
Interestingly, hybrids formed between the revertant, G2, and the
normal fibroblasts, FR3T3, also displayed sensitivity to MGBG.
These observations suggested that two clones résistant to MGBG
are capable of complémentation and the MGBG résistance phenotype
is controled by différent genes.
From the above results we concluded that the revertant G2
cells possess a cellular mutation that is dominant. This mutation
has the ability to block the adeno-El-induced transformation
process. Furthermore, the G2 cells carry a second mutation,
récessive in nature, affecting the transport of MGBG across the
cell membrane.
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Figure 12 Immunoprecipitation of ElA proteins from F4, G2 and
hybrid cells.
Cells were labeled with (^^S) methionine and lysates were
precipitated as described in Materials and Methods. The
precipitated proteins were separated on 9% polyacrylamide
gels and detected by autoradiography. Lanes from right to
left are: Ad2: the adenovirus-2 labeled marker; F4: the
adenovirus-transformed rat cell line; G2 : the MGBG^-
revertant cell line; hybrids: FF (F4xF4); GF (G2xF4), three
independent clones were used; 3F (F4xFR3T3), three
independent clones were used; 3G (G2xFR3T3), two clones were
used; and 3T3: the normal FR3T3 cell line. The open arrow,
< RB, points to the position where the 105Kb protein of the
RB gene which binds to ElA proteins (Whyte et al., 1988;
1989) is thought to migrate.
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DISCUSSION
The présent work was focused on the characterisation of rat
somatic cell mutants that can be used as tools to investigate
cell transformation. The objective was the isolation of a cell
line expressing a tumor suppressing gene or antioncogene. To
achieve this goal, MGBG résistant mutants were selected from an
Ad2-transformed rat cell line and these cells were used initially
to study the link, if any, between drug résistance and cell
transformation. MGBG being an anticancer drug, we reasoned that
it would selectively kill transformed cells. Indeed, the MGBG^
cells were observed to exhibit a non-transformed (detransformed)
phenotype. Results presented here strongly suggest that there is
no direct relationship between the development of MGBG résistance
and cellular detransformation. It is likely that, according to
the above rationale, detransformation was a co-selected marker
along with MGBG résistance.
Our approach to isolate detransformed variants, résistant to
MGBG, from the parental adenovirus transformed rat cells was
similar to that of Noda et al. (1983) . These investigators could
Select for flat cellular revertants from Kirsten murine sarcoma
virus-transformed cells (i.e. drug-resistant transformation
mutants) by using ouabain résistance as a genetic marker. We
used MGBG rather than ouabain to isolate mutants this study for
the following reasons: (1) the Ad2-transformed cells (F4) were
naturally résistant to ouabain, (2) MGBG can specifically kills
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transformed cells (Rupniak and Paul, 1980; 1978), (3) drug
résistant variants are likely to be membrane transport mutants
(Kartner et al., 1985; Gottesman, 1987) and (4) the cell membrane
plays an important rôle in expression of the transformed
phenotype (Till et al., 1973; Warren et al., 1973).
The adenovirus tranformed rat cell line F4, was chosen for
this study because, among several transformed cell lines tested
it was found to be most sensitive to MGBG (Sircar et al., 1987),
and secondly, this cell line posseses multiple copies of the
adenovirus El transforming région (Flint, 1981). Presence of the
multiple viral gene copies was useful in order to avoid
selecting mutations in the viral oncogenes. Différent protocols
were followed to select several indépendant transformation
revertants (Table 1) which might be expected to be defactive in
différant aspects of the transformation phenotype.
Drug (MGBG) résistance exhibited by the transformed cell
revertants may operate on three différant phenomena (individually
or simultaneously). On exposure to drugs, the cells may produce
an elevated amount of the target component (e.g. receptor,
enzyme, precursor, etc.) or the cellular target may alter its
affinity for the drug (i.e. the target receptor may have an
altered or différant st2ructure resulting in reduced/increased
affinity for the drug) and the cellular influx/efflux of the drug
may be affected. The data obtained revealed that résistant
cells were obtained in a single step sélection. The isolation
frequency of these variants was approximately 10~®. Since the
frequency was very low and the resuit of single-step sélection,
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these mutants are believed to carry a mutation affecting a single
gene responsible perhaps for detransformation and/or for
résistance to the drug. The drug résistance phenotype was stable
in the absence of sélection pressure for four years. This
observation further implied that the MGBG résistance phenotype
had a genetic origin. MGBG has several intracellular binding
sites (Pegg and McCann, 1982; Janne and Morris, 1984) due to its
positive charge at physiological pH. One of the key sites
affected by MGBG in cellular metabolism is the SAM decarboxylase
(SAMDC), the second rate limiting enzyme in polyamine metabolism.
Since the résistance phenotype appeared to be of genetic origin,
this enzyme was examined in différent independent cell lines
(Table 2) . The MGBG^ cells did not show more than normal SAMDC
activity as compared to the MGBG® F4 cells and the enzyme
activity was inhibited by MGBG to the same extent in ail cell
types. This resuit suggested that the enzyme from various cell
lines, including the F4 parental as well as MGBG^ cells, was
equally sensitive to the inhibitor (MGBG) and ruled out the
possibility that the drug résistance of the cells was due to the
production of a mutated enzyme.
Since the target enzyme, SAMDC, was not responsible for the
drug résistance phenotype exhibited by the MGBG^ cells, the drug
transport mechanism (influx/efflux) of these cells was examined.
The most common cause for drug résistance of the cells is reduced
drug uptake due to altered cell membrane properties (Kartner et
al., 1985). In ail the variants reported here, résistance was
due to an altération in the accumulation of the drug. In
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in the MGBG^ cells (Figure 5), suggesting that the number of drug
transport sites was lower. Similar results were observed when
the uptake of spermidine by these cells was investigated (Table
3) . MGBG is a structural analogue of spermidine and both of
these compounds are transported into the cell through the same
transport systein (Field et al., 1964; Alhonen-Hongisto et al.,
1985) . The rate of MGBG efflux was not significantly différent
between the MGBG^ and the MGBG^ cells (Figure 6) . This resuit
strongly suggests that the intracellular binding sites for the
drug in the MGBG® F4 cells and the MGBG^ cells release or bind
the drug to a similar extent and were not altered. Thus, MGBG^
cells appear to be résistant to the drug due to a decreased
intracellular transport of the compound. Similar properties were
exhibited by a mouse leukemia line L 1210 (Mihich, 1967; Dave and
Caballes, 1973; Mihich et al., 1974) and CHO cells (Mandell and
Flintoff, 1978) that were selected for résistance to MGBG.
Fusion analysis of the MGBG^ cell lines show the drug
résistance phenotype of these cells is récessive (Table 5) as
determined by the degree of résistance to MGBG. The récessive
drug résistance phenotype was reported earlier for MGBG-
resistant lines of Chinese hamster ovary cells (CHO) and rat
myoblast cells (Lg) (Flintoff et al., 1976; Mandel and Flintoff,
1978) . Hybrids formed between the MGBG résistant variant (G2)
and the untransformed FR3T3 cells complemented each other for
sensitivity to MGBG. Similar results have also been observed
between two MGBG résistant lines of CHO mutants defective in drug
uptake (Heaton and Flintoff, 1988) . A possible explanation for
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the complémentation in these cells is that drug résistance is
genetically controlled by more than one locus. It appears that the
MGBG-resistant variants selected in this study, i.e. as apposed
to drug-resistant FR3T3, are drug transport mutants defective in
uptake of the chemical and are phenotypically récessive.
Since the goal of this investigation was to isolate
transfoinnation-mutants (cells exhibiting a normal phenotype), the
drug résistant cells were tested for transformation-related
properties. Several of the isolated MGBG^ (see Table 1) variants
were characterized and found to display the transformation
revertant phenotype i.e. these oeil lines (i) had a flat
morphology, (ii) exhibited anchorage-dependence, (iii) did not
produce tumors in nude mice and (iv) most possessed the viral
transforming genes integrated into the cellular genome. However,
among the varions mutants studied, only one of the isolated MGBG
oeil lines met ail the criteria expected of a cell line
expressing an antioncogene. The G2 cells had a nontransformed
phenotype, apparently the resuit of a cellular mutation and not
due to the loss or inactivation of the viral transforming ElA or
ElB genes. The key properties of G2 cells which suggest that
they carry a tumor suppressor gene are as follows:
(1) G2 have a normal, detransformed phenotype,
(2) they have this phenotype in spite of the presence and
normal expression of the El genes as determined by (i)
Southern blotting (Sircar et al., 1987), (ii) Northern
analysis (Weber et al., manuscript submitted) (iii)
immunoprecipitation (Sircar et al., 1987), (iv) résistance
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to retransformation by El plasmids but not other oncogenes
(Sircar et al., 1988), (v) ElA proteins expressed in G2 can
complément the replication of an ElA deletion mutant, (vi)
G2 cells are susceptible to ElA-mediated cell lysis by TNF,
(3) G2 is dominant over F4 in cell hybrids,
(4) FR3T3 fails to restore the transformed phenotype in cell
hybrids with G2, by complémentation.
The rest of the MGBG^ variants that displayed the
transformation revertant phenotype were unable to complément the
replication of an ElA deletion mutant virus, to induce TNF-
cytolysis or form tumors in nude mice (see Fig 7, Fig 8 and Table
4) . Consistent with these data these cells did not express the
Ad-EIA proteins (Table 4). The detransformed phenotype exhibited
by these cells was due either to inactivation or loss of El genes.
TNF is produced by activated macrophages and can cause
mortality especially to cells that express the adenovirus ElA
proteins (Chen et al., 1987). An attempt to search for the
mechanism(s) of the TNF-induced cell lysis of ElA expressing
cells, based on the following facts: (a) TNF can stimulâtes c-
mvc expression in human transformed cells (Kirstein and
Baglioni,1988), (b) ElA proteins are présent on the cell surface
of adenovirus-transformed cells, in addition to its prédominant
location in the nucleus (Bellgrau et al., 1988), (c) ElA is a
myc-like oncogene (Zerler et al., 1986; Figge et al., 1988) and
(d) overexpression of ElA proteins can be toxic to certain cells
(Jochemsen et al., 1987). Results obtained from the présent
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study show that TNF did not stimulate either ElA or c-myc
expression in our cell system. Cells retransformed by 5-
azacytidine to détermine whether DNA methylation played any rôle
in expression of these genes (Weber et al., manuscript submitted)
(and therefore inducing TNF lysis) suggested that demethylation
was not involved in TNF cytolysis. It appears that (1) the
transformed phenotype was not required for TNF cytolysis as long
as ElA was expressed and (2) a threshold level of ElA expression
was required to induce TNF susceptibility. These observations
suggest that ElA itself plays a rôle in inducing susceptibility
to TNF and that cellular transformation per se has no effect on
TNF cytolysis.
Recently, cellular transformation by ElA was shown to
require other functions besides transactivation. It was based on
the observation that expression of both ElA proteins, 289R and
243R, was required to obtain complété cellular transformation,
although each ElA protein by itself was sufficient to induce
partial transformation of the cell (Haley et al., 1984; Montell
et al., 1984; Moran et al., 1986). There is a possibility that
domains 1 and 2, on each ElA protein, are not functional in the
G2 cells. However, this is quite unlikely because studies
performed by Sircar et al. (1988) demonstrated that the G2 cells
express the ElA proteins and were résistant to retransformation
by El bearing plasmids. These observations strongly suggest that
the revertant phenotype is due to a mutation(s) in a cellular
gene(s).
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The ElA proteins shown to associate with the RB gene
product in both adenovirus-infected and adenovirus-transformed
cells (Whyte et al., 1988). The RB protein binds to domains 1
and 2 of the ElA proteins (Whyte et al., 1989). Because a
similar binding between RB and the oncoproteins of SV40, polyoma
and human papilloma virus was also found, a hypothesis emerged
according to which these oncoproteins transform cells by
inactivating RB, thereby mimicing in vivo cancers where RB is
deleted. It is possible that the ElA proteins in the revertant G2
cells do not bind to the RB proteins in these cells and therefore
the cells are not transformed. The immunoprecipitation results
with ElA monoclonal antibodies (Fig 12, lane G2) show a protein
band migrating at a similar position on the SDS-PAGE gel as the
105kDa-RB protein observed by Whyte et al., (1988). It appears
therefore that binding between RB and ElA is normal and the G2
antioncogene exerts its effect elsewhere in the transformation
pathway. This resuit also suggests that although binding between
RB and ElA may be necessary, it is not sufficient for cell
transformation.
Since the above data provided evidence that the revertant
phenotype was due to an altération in the cellular DNA, this
phenotype was expected to display a dominant character when these
cells were fused with the parental (transformed) cells. Results
obtained from the fusion studies confirmed this expectation (see
Table 5, fusion between G2 revertant and F4 transformed cells).
The nontumorigenic phenotype of the hybrids, however, is not the
resuit of the loss of the viral genome, as shown by their
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continued expression of ElA (Fig 12 and Table 5) . Furthenaore,
the possibility that the G2 revertant cells may be déficient in a
physiologically relevant component that is expressed under normal
growth conditions was ruled out based on results which showed
that the hybrid cells formed between G2 and FR3T3 were not
transformed (Table 5). The apparent lack of a cellular defect in
production of the transformation phenotype supports the
hypothesis that the G2 revertant has a cellular mutation(s)
affecting a gene(s) in the pathway normally responsive to the
effects of the ElA transformiing gene. Presumably, this gene is
responsible for suppression of the tumorigenicity in these cells.
Because of the limitations of the fusion technique (instability
of the hybrids and high chromosome content per cell) these
results must be confirmed by an independent approach such as the
DNA-transfer technique.
77
REFERENCES
Aderka, D. , Holtmann, H., Toker, L. , Hahn, T. and Wallach, D.
(1986). Tumor necrosis factor induction by Sendai virus.
J. Immunol. 136: 2938-2942.
Aggarwal, B.B., Essalu, T.E., and Hass, P.E. (1985).
Characterisation of receptors for human tumor necrosis
factor and their régulation by -interferon. Nature 318:
665-667.
Alestrom, P., Aksusjarvi, G., Perricaudet, M., Mathews, M.B.,
Klessig, D.F., and Pettersson, U. (1980). Structure of the
gene for polypeptide IX and its unspliced messenger RNA.
Cell 19: 671-681.
Alhonen-Hongisto, L. , Levin, V.A., and Marton, L.J. (1985).
Modification of uptake and antiproliferative effect of
methylglyoxal bis(guanylhydrazone) by treatment with -
difluromethylornithine in rodent cell lines with différent
sensitivities to methylglyoxal bis(guanylhydrazone). Cancer
Res. 45: 509-514.
Allen, R.R., and Klinman, J.P. (1981). Sterochemistry and
Kinetic isotype effects in the decarboxylation of S-
adenosylmethionine catalyzed by the pyruvyl enzyme, S-
adenosylmethionine decarboxylase. J. Biol. Chem. 256: 3233-
3239.
Alt, F., Rosenberg, N. , Lewis, S., Thomas, E. and Baltimore, D.
(1981). Organization and Reorganization of Immunoglobulin
genes in A-MuLV- transformed cells: Rearrangement of Heavy
not light chain genes. Cell 27: 381-390.
Anderson, C.W., Schmitt, R.C., Smart, J.E. and Lewis, J.B.
(1984). Early région El of adenovirus 2 encodes two
cotejrminal proteins of 495 and 155 amino acid residues. J.
Virol. 50: 387-396.
Babiss, L.E. and Ginsberg, H.S. (1984). Adenovirus type 5 early
région Ib gene product is required for efficient shutoff of
host protein synthesis. J. Virol. 50:202-212.
Babiss, L.E. Ginsberg, H.S., and Darnell Jr. J.E. (1985).
Adenovirus Elb proteins are required for accumulation of
late viral mRNA and for effects on cellular mRNA translation
and transport. Mol. Cell. Biol. 5: 2552-2558.
Babiss, L.E., Young, C.S.H., Fisher, P.B., and Ginsberg, H.S.
(1983). Expression of adenovirus Ela and Elb gene products
and the Escherichia coli XGPRT gene in KB cells. J. Virol.
46: 454-465.
78
Balkwill, F.R. (1989). Tumor necrosis factor. Br. Med. Bull. 45:
389-400.
Barker, D.D., and Berk, J. (1987). Adenovirus proteins from ElB
reading frames are required for transformation of rodent
cells by viral infection and DNA transfection. Virology
156: 107-121.
Bassin, R.H. and Noda, M. (1987) . Oncogene inhibition by
cellular genes. Adv. Viral. Oncol. 6: 103-127.
Bauer, M., Guhl, E., Graessmann, M., and Graessmann, A. (1987).
Cellular Mutation médiates T-antigen-positive revertant
cells résistant to simian virus 40 transformation but not to
retransformation by Polyomavirus and Adenovirus type 2. J.
Virol. 61: 1821-1827.
Bellgrau, D., Walker, T.A., and Cook, J.L. (1988). Récognition
of adenovirus Ela gene products on immortalized cell
surfaces by cytotoxic T lymphocytes. J. Virol. 62: 1513-
1519.
Berk, A.J. (1986). Adenovirus promoters and ElA transactivation.
Ann. Rev. Genet. 20: 45-79.
Berk, A.J., and Sharp, P.A. (1978). Structure of adenovirus 2
early mRNAs. Cell 17: 935-944.
Beulter, B., and Cerami, A. (1987). Cachectin: More than a tumor
necrosis factor. N. Engl. J. Med. 316: 379-385.
Beutler, B. , and Cerami, A. (1988a). Cachectin, Cachexia and
Shock. Ann. Rev. Med. 39: 75-83.
Beutler, B., and Cerami, A. (1988). The common mediator of
shock, cachexia and tumor necrosis. Adv. Immunol. 42: 213-
231.
Beutler, B., and Cerami, A. (1988b). Tumor necrosis, cachexia,
shock and inflammation: a common mediator. Ann. Rev.
Biochem. 57: 505-518.
Beutler, B., Krochin, N., Milsark, I.W., Luedke, C., and Cerami,
A. (1986). Control of cachectin (tumor necrosis factor)
synthesis: Mechanisms of endotoxin résistance. Science 232:
977-980.
Bishop, J.M. (1983). Cellular oncogenes and retroviruses. Ann.
Rev. Biochem. 52: 350-354.
Blochlinger, K. , and Diggelmann, H. (1984), Hygromycin B
phosphotransferase as a selectable marker for DNA transfer
experiments with higher eucaryotic cells. Mol. Cell. Biol.
4: 2929-2931.
79
Borrelli, E., Hen, R., and Chambon, P. (1984). Adenovirus-2 ElA
products repress enhancer-induced stimulation of
transcription. Nature 312: 608-612.
Bos, J.L., Polder, L.J., Bernards, R., Schrier, P.I., van den
Elsen, P.J., van der Eb, A. J. , and van Ormondt, H. (1981).
The 2.2Kb Elb mRNA of human adl2 and adS codes for two tumor
antigens starting at différent AUG triplets. Cell 27: 121-
131.
Branton, P.E., Bailey, S.T., and Graham, F.L. (1985).
Transformation by Human adenoviruses. Biochem. Biophys.
Acta. 780: 67-94.
Brenner, M.K. (1988). Tumor necrosis factor. Brit. J. Haematol.
69: 149-152.
Caput, D., Beutler, B., Hartog, K., Brown-Shimer, S., and Cerami,
A. (1986). Identification of a common nucleotide sequence
in th 3'-untranslated région of mRNA molécules specifying
inflammatory mediators. Proc. Natl. Acad. Sci. USA 83:
1670-1674.
Carlock, L.R., and Jones, N.C. (1981). Transforming-defective
mutant of adenovirus type 5 containing a single altered ElA
mRNA species. J. Virol. 40: 657-664.
Carswell, E.A., Old, L.J., Kassel, R.L., Green, S., Fiore, N. ,
and Williamson, B. (1975). An endotoxin-induced sérum
factor that causes necrosis of tumors. Proc. Natl. Acad.
Sci. USA 72: 3666-3671.
Celeste Simon, M., Kitchener, K., Kao, H.-T., Hickey, E., Weber,
L., Voellmy, R., Heintz, N., and Nevins, J.R. (1987).
Sélective induction of human heat shock gene transcription
by the adenovirus ElA gene products, including the 12S ElA
product. Mol. Cell. Biol. 7: 2889- 2890.
Cepko, C.L., Roberts, B.E., and Mulligan, R.C. (1984).
Construction and applications of a highly transmissible
murine retrovirus shuttle vector. Cell 37: 1053-1062.
Chen, M.-J., Holskin, B., Strickler, J. , Gorniak, J. , Clark,
M.A. , Johnson, P.J., Mitcho, M., and Shalloway, D. (1987).
Induction by ElA oncogene expression of cellular
susceptibility to lysis by TNF. Nature (London) 330: 581-
583.
Cho, H.Y., Cutchins, E.C., Rhim, J.S., and Huebner, R.J. (1976).
Revertants of human cells transformed by murine sarcoma
virus. Science 194: 951-953.
Chow, L.T., Broker, T.R., and Lewis, J.B. (1979). Complex
splicing patterns of RNAs from the early régions of
adenovirus-2. J. Mol. Biol. 134: 265-303.
80
Coley, W.B. (1893). The treatment of malignant tumors by
repeated inoculations of erysipelas: with a report of ten
original cases. Aiti. J. Med. Sci. 105: 487-511.
Cordingley, F.T., Blanchi, A., Hoffbrand, A.V., Reittie, J.E.,
Heslop, H.E., Vyakarnam, A., Turner, M., Meager, A., and
Brenner, M.K. (1988a). Tumor necrosis factor as an autocrine
tumor growth factor for chronic B-cell malignancies. Lancet
1: 969-971.
Cordingley, F.T., Hoffbrand, A.V. and Brenner, M.K. (1988b).
Cytokine-induced enhancement of the susceptibility of hairy
cell leukemia lymphocytes to naturel killer cell lysis. Br.
J. Haematol. 70: 37-41.
Corti, A., Dave, G., Williams-Ashman, H.G., Mihich, E., Schenone,
A., (1974). Spécifie inhibition of the enzyme
decarboxylation of s-adenosylmethionine by methylglyoxal-
bis(gyanylhydrazone) and related substancae. Biochem. J.
139: 351-357.
Craig, R.W., and Sager, R. (1985). Suppression of tumorigenicity
in hybrids of normal and oncogene-transformed CHEF cells.
Proc. Natl. Acad. Sci. USA 82: 2062-2066.
Crawford, L. (1983). The 53,000-dalton cellular protein and its
rôle in transformation. Int. Rev. Exp. Pathol. 25: 1-50.
Daves, C., and Caballas, L. (1973). Studies on the uptake of
methylglyoxal bis(guanylhydrazone) (CH3-G) and spermidine in
mouse leukemia LI210/CH3-G) . Fed. Proc. 32: 736 (abs
#2940).
Dealtry, G.B., Naylor, M.S., Fiers, W., and Balkwill, F.R.
(1987). The effect of recombinant human TNF on growth and
macro-molecular synthesis of human epithelial cells. Exp.
Cell Res. 170: 428-433.
Dodson, M.G., Slota, J., Lange, C. , and Major, E. (1981).
Distinction of the phenotype of in vitro anchorage-
independent soft-agar growth in in vitro tumorigenicity in
nude mice. Cancer Res. 41: 1441-1446.
Duesberg, P.H. (1987). Retrovirus as Carcinogens and Pathogens:
Expectations and Reality. Cancer Res. 47: 1190-1220.
Eliyahu, D., Raz, A., Gruss, P., Givol, D. and Oren, M. (1984).
Participation of p53 cellular tumor antigen in
transformation of normal embryonic cells. Nature 312: 646-
649.
Feldman, L.T., Impériale, M.J., and Nevins, J.R. (1982).
Activation of early adenovirus transcription by the herpes
virus immédiate early gene: Evidence for a common cellular
control factor. Proc. Natl. Acad. Sci. USA 79: 4952-4956.
81
Ferguson, B., Krippl, B., Andrisani, 0., Jones, N., Westphal, H.,
and Rosenberg, M. (1985) . ElA 13S and 12S mRNA products
made in Esherichia col i both functioanl as nucleus-
localized transcription activators but do not directly bind
DNA. Mol. Cell. Biol. 5: 2653-2661.
Field, M., Block, J.B., Oliveno, V.T., and Rail, O.P. (1964).
Cellular accumulation of methylglyoxal-bis-guanylhydrazone
in vitro I. General characteristics of cellular uptake.
Cancer Res. 24: 1939-1946.
Fiers, W., Beyaert, R., Brouckaert, P., Eueraerdt, B., Haegeman,
C., Suffys, P., Tavernier, J., and Vanhaesebroeck, B.
(1988). TNF: Its potential as as antitumor agent. Develop.
Biol. Standard. 69: 143-151.
Figge, J., Webster, T., Smith, T.F., and Paucha, E. (1988).
Prédiction of similar transforming régions in Simian Virus
40 Large T, Adenovirus ElA, and myc Oncoproteins. J. Virol.
62: 1814-1818.
Fisch, H., and Gifford, G.E. (1983). In vitro production of
rabbit macrophage tumor cell cytotoxin. Int. J. Cancer 32:
105-112.
Fischinger, P.J., Nomura, S., Peebles, P.T., Haapala, D.K., and
Bassin, R.H. (1972). Reversion of murine sarcoma virus
transformed mouse cells: variants without a rescuable
sarcoma virus. Science 176: 1033-1035.
Fletcher, W.H., Shiu, W.W., Ishida, T.A., Haviland, D.L., and
Ware, C.F. (1987). Résistance to the cytolytic action of
lymphotoxin and Tumor necrosis factor coincides with the
presence of Gap junctions uniting target cells. J. Immunol.
139: 956-962.
Flint S.J. (1987). Cellular transformation by adenoviruses. In:
D. Grunberger and S. Goff (eds.) Mechanisms of cellular
transformation by carcinogenic agents. pp. 237- 269.
Pergamon press Itd.
Flint, S.J. (1981). In: J. Tooze (ed.)., DNA Tumor Viruses, Cold
Spring Harbor, New York, Cold Spring Harbor Laboratory.
pp. 383-442.
Flint, J. (1977). The topography and transcription of the
adenovirus genome. Cell 10: 153-166.
Flintoff, W.F., Davidson, S.V., Siminovitch, L. (1976).
Isolation and partial characterization of three methotrexate
résistant phenotypes from Chinese hamster ovary cells.
Somatic Cell Gen., 2: 245-261.
82
Freedlander, B.L., and French, F.A. (1958). Carcinostatic Action
of Polycarbonyl compounds and their derivatives. II.
Glyoxal Bis (Guanylhydrazone) and Derivatives. Cancer Res.
18: 360-363.
Frei, E., and Spriggs, D. (1989). Tumor Necrosis Factor: Still a
proitiising agent. J. Clin. Oncol. 7: 291-294.
French, F.A., Freedlander, B.L., Hasking, A., and French, J.
(1960). Carcinostatic activity of some dicarbonyl compounds
and their bis(hydrazones). Acta. Uni. Int. Contra Cancrum.
16: 614-624.
Gallimore, P.H. (1974). Interactions of adenovirus type 2 with
rat embryo cells: Permissiveness, transformation and in
vitro characteristics of adenovirus transformed rat embryo
cells. J. Gen. Virol. 25: 263-273.
Gallimore, P.H., Byrd, P.J., Whittaker, J.L., and Grand, R.J.A.
(1985b). Properties of Rat cells transformed by DNA
plasmids containing Adenovirus Type 12 El DNA or spécifie
fragments of the El région: Comparison of transforming
Frequencies. Cancer Res. 45: 2670-2680.
Gallimore, P.H., McDougall, J.K., and Chen, L.B. (1977). In
vitro traits of adenovirus-transformed cell lines and their
relevance to tumorigenicity in nude mice. Cell 10: 699-678.
Gallimore, P.H., Sharp, P.A., and Sambrook, J. (1974). Viral
DNA in transformed cells II. A study of the sequences of
adenovirus 2 DNA in nine lines of transformed rat cells
using spécifie fragments of the viral genome. J. Mol. Biol.
89: 49-72.
Gardella, T., Medviczky, P., Sairenji, T., and Mulder, C. (1984).
Détection of circular and linear herpesvirus DNA molécules
in mammalian cells by gel electrophoresis. J. Virol. 50:
248-254.
Glenn, G.M., and Ricciardi, R.P. (1985). Adenovirus 5 early
région lA host range mutants hr3, hr4, and hr5 contain point
mutations which generate single amino acid substitutions.
J. Virol. 56: 66-74.
Gooding, L.R., Elmore, L.W., Tollefson, A.E., Brady, H.A., and
Wold, W.S.M. (1988). A 14,700 MW protein from the E3 région
of adenovirus inhibits cytolysis by tumor necrosis factor.
Cell 53: 341-346.
Gordonsmith, R.H., Brook-Taylor, S., Smith, L.L., and Cohen, G.M.
(1983). Structural requirements of compounds to inhibit
pulmonary diamine accumulation. Biochem. Pharmacol. 32:
3701-3709.
83
Gottesman, M.M. (1987). Drug-resistant mutants: selecting and
dominance analysis. Methods in Enz. 151: 113-121.
Graham, F.L. (1984). Transformation by and oncogenicity of human
adenovirus. In: Ginsberg H. (ed) The Adenoviruses. Plénum,
New York, pp. 339-398.
Grand, R.J.A. (1987). The structure and function of the
adenovirus early région 1 proteins. Biochem. J. 241: 25-38.
Green, M.R., Chinnadurai, G., Mackey, J.K., and Green, M. (1976).
A unique pattern of integrated viral genes in hamster cells
transformed by highly oncogenic human adenovirus 12. Cell
7: 419-428.
Green, M., Pina, M., Kimes, R. , Wensink, P.C., Machattie, L.A. ,
Thomas, C.A. (1967). Adenovirus DNA I. Molecular Weight
and configuration. Proc. Natl. Acad. Sci. USA 57: 1302-
1309.
Green, A.R. and Wyke, J.A. (1985). Anti-oncogenes a subset of
regulatory genes involved in carcinogenesis. Lancet ii:
475-477.
Green, M.R. (1989) . When the products of oncogenes and anti-
oncogenes meet. Cell 56: 1-3.
Greenberger, J.S., and Aaronson, S.A. (1974). Morphological
revertants of murine sarcoma virus transformed nonproducer
Balb/3T3: sélective techniques for isolation and biologie
properties in vitro and in vivo. Virology 57: 339-346.
Gupta, R.S. (ed.) (1989). Drug Résistance in Mammalian cells.
Vol II. Anticancer and other drugs. CRC Press, Inc.
Hahn, T., Toker, L., Budilovsky, S., Aderka, D., Eshhar, Z., and
Wallach, D. (1985). Use of monoclonal antibodies to a human
cytotoxin for its isolation and for examining the self-
induction of résistance to this protein. Proc. Natl. Acad.
Sci. USA 82: 3814-3818.
Haley, K.P., Overhauser, G., Babiss, L.E., Ginsberg, H.S., and
Jones, N.C. (1984). Transformation properties of type 5
adenovirus mutants that differentially express the ElA gene
products. Proc. Natl. Acad. Sci. USA 81: 5734-5738.
Harlow, E., Franza, B., and Schley, C. (1985). Monoclonal
antibodies spécifie for adenovirus early région lA proteins:
Extensive heterogeneity in early région lA products. J.
Virol. 55: ,533-546.
Harlow, E., Whyte, P., Franza, Jr., B.R., and Schley, C. (1986).
Association of adenovirus early-region lA proteins with
cellular polypeptides. Mol. Cell. Biol. 6: 1579-1589.
84
Harris, H., Miller, O.J., Klein, G., Worst, P. and Tachibana, T.
(1969). Suppression of malignancy by cell fusion. Nature
223: 363-368.
Haynes, J.R., and Downing, J.R. (1988). A récessive cellular
mutation in v-fes-transformed mink cells restores contact
inhibition and anchorage-indépendant growth. Mol. Cell.
Biol. 8: 2419-2427.
Heaton, M.A., and Flintoff, W.F. (1988). Methylglyoxal-
bis(guanylhydrazone)-résistant Chinese Hamster Ovary cells:
Genetic evidence that more than a single locus controls
Uptake. J. Cell. Physiol. 136: 133-139.
Helson, L., Green, S., Carswell, E.A., and Old, L.J. (1975).
Effect of tumor necrosis factor on cultured human melanoma
cells. Nature 258: 731-732.
Hen, R., Borrelli, E. , and Chambon, P. (1985). Repression of
the immunoglobulin heavy chain enhancer by the adenovirus-2
ElA products. Science 230: 1391-1394.
Herbst, R.S., Hermo, H. Jr. , Fisher, P.B., and Babiss, L.E.
(1988). Régulation of adenovirus and cellular gene
expression and of cellular transformation by the ElB-
encoded 175-amino acid protein. J. Virol. 62:4634-4643.
Herr, H.W., Kleinert, E.L., Conti, P.S., Burchenal, J.H., and
Whitmore, W.F. (1984). Effects of -Difluoromethylornithine
and Methylglyoxal bis(guanylhydrazone) on the growth of
expérimental rénal adenocarcinoma in mice. Cancer Res. 44:
4382-4385.
Hinds, P.W., Finlay, C.A., Frey, A.B. and Levine, A.J. (1987).
Immunological evidence for the association of p53 with a
heat.shock protein, hsp 70, in p53-plus-ras-transformed cell
lines. Mol. Cell. Biol. 7: 2863-2869.
Hinds, P., Finlay, C., and Levine, A.J. (1989). Mutation is
required to activate the p53 gene for coopération with the
ras oncogene and transformation. J. Virol. 63: 739-746.
Hotez, P.J., Le Trang, N., Fairlamb, A.H. and Cerami, A. (1984).
Lipoprotein lipase suppression in 3T3-Li cells lay a
haematoprotozoan-induced mediator from peritoneal exudate
cells. Parasite Immunol. 6: 203-209.
Houweling, A., van den Elsen, P.J., and van der Eb, A.J. (1980).
Partial transformation of primary rat cells by the leftmost
4.5% fragment of adenovirus 5 DNA. Virology 105: 537-550.
Huebner, R.J., Rowe, W.P., Lane, W.T. (1962). Oncogenic effects
in hamster of human adenovirus type 12 and 18. Proc. Natl.
Acad. Soi. USA 48: 2051-2058.
85
Impériale, M.J., Kao, H-T., Feldman, L.T., Nevins, J.R. and
Strickland, S. (1984). Common control of the heat shock
gene and early adenovirus genes: evidence for a cellular
ElA-like activity. Mol. Cell. Biol. 4: 875-882.
Impériale, M.J., Feldman, L.T., and Nevins, J.R. (1983).
Activation of gene expression in DNA-transfections by
adenovirus and herpesvirus regulatory genes acting in trans
and by a cis-actina adenovirus enhancer element. Cell 35:
127-136.
Inoue, H., Owada, M.K., Yutsudo, M., and Hakura, A. (1989). A
Rat mutant cell clone showing temperature-dependent
transformed phenotypes with functional expression of src
gene product. Virology 168: 57-66.
Inoue, H., Yutsudo, M., and Hakura, A. (1983). Rat mutant cells
showing température sensitivity for transformation by
wild type Moloney murine sarcoma virus. Virology 97:231-
240.
Israël, M.S. (1962). The viral flora of enlarged Tonsils and
Adenoids. J. Path. Bact. 84: 169-176.
Janne, J., and Morris, D.R. (1984). Inhibition of S-
adenosylmethionine decarboxylase and diamine oxidase
activities by analogues of methylglyoxal bis(guanylhydra-
zone) and their cellular uptake during lymphocyte
activition. Biochem. J. 218: 947-951.
Janne, J., Alhonen-Hongisto, L., Nikula, P., and Elo, H. (1985).
S-adenosylmethionine decarboxylase as target of
chemotherapy. Adv. Enz. Reg. 24: 125-139.
Jelinek, D.F., and Lipsky, P.E. (1987). Enhancement of human B
cell prolifération and differentiation by tumor necrosis
factor-a and interleukin 1. J. Immunol. 139: 2970-2976.
Jenkins, J.R., Rudge, K. , and Currie, G.A. (1984). Cellular
immortalization by a cDNA clone encoding the transformation-
associataed phosphoprotein p53. Nature 312: 651-654.
Jochemsen, A.G., Peltenburg, L.T.C., te Pas M.F.W., de Wit, C.M.,
Bos J.L. and van der Eb, A.J. (1987). Activation of
adenovirus 5 ElA transcription by région ElB in transformed
primary rat cells. EMBO J. 6:(11) 3399-3405.
Johnson, M.D., Housey, B.M., Kirschmeier, P.T., and Weinstein,
I.B. (1987). Molecular cloning of gene sequences regulated
by tumor promoters and mitogens through protein kinase C.
Mol. Cell. Biol. 7: 2821-2829.
Jones, N., and Shenk, T. (1979). Isolation of adenovirus type 5
host range deletion mutants defective for translation of rat
embryo cells. Cell 17: 683-689.
86
Kallio, A., Seppanen, P., Alhonen-Hongisto, L., and Janne, J.
(1983). Modulation of the Tissus Disposition of
methylglyoxal bis(guanylhydrazone) in mice by polyamine
depletion and by polyamine administration. Cancer Res. 43:
324-327.
Kao, H-T., and Nevins, J.R. (1983). Transcription activâtion and
subséquent control of the human beat shock gens during
adenovirus infection. Mol. Cell. Biol. 3: 2058-2065.
Kartner, N., Evernden-Porelle, D., Bradley, G., and Ling, V.
(1985). Détection of P-glycoprotein in multidrug-resistant
cell lines by monoclonal antibodies. Nature (London) 316:
820-823.
Karvonen, E., and Peso, H. (1984). Stabilization of ornithine
decarboxylase and N'-spermidine acetyltransferase in rat
liver by methylgloxal bis(guanylhydrazone). Biochim.
Biophys. Acta. 791: 239-243.
Katz, E., and Carter, B.J. (1986). A mutant cell line derived
from NIH3T3 cells: two oncogenes required for in vitro
transformation. J. Natl. Cancer Inst. 77: 909-914.
Kimmelman, D. , Miller, J.S., Porter, D. , and Roberts, B.E.
(1985). ElA régions of the human adenoviruses and the
highly oncogenic simian adenovirus 7 are closely related.
J. Virol. 53: 399-409.
King, W., Patel, M.D., Lobel, L.I., Goff, S.P., and Nguyen-Huu,
M. C. (1985). Insertion mutagenesis of embryonal carcinoma
cells by retroviruses. Science 228: 554-558.
Kingsnorth, A.N. (1986). The chemotherapeutic potential of
polyamine antimetabolites. Ann. Royal Coll. of Surg. 68:
76-81.
Kingston, R.E., Baldwin, A.S., and Sharp, P.A. (1985).
Transcription control by oncogenes. Cell 41: 3-5.
Kirstein, M., and Baglioni, C. (1988). Tumor necrosis factor
stimulâtes prolifération of human osteosarcoma cells and
accumulation of c-myc messenger RNA. J. Cell. Physiol. 134:
479-484.
Kitayana, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y., and Noda,
M. (1989). A ras-related gene with transformation
suppressor activity. Cell 56: 77-84.
Klein, G. (1988). Tumpr suppressor genes. J. Cell Soi. Suppl.
10: 171-180.
Klein,G., and Klein, E. (1985). Evolution of tumors and the
impact of molecular oncology. Nature 315: 190-195.
87
Klinger, H.P. and Shows, T.B. (1983). Suppression of
tumorigenicity in somatic cell hybrids II. Human
chromosomes implicated as suppressors of tumorigenicity in
hybrids with Chinese hamster ovary cells. J. Natl. Cancer
Inst. 71: 559-569.
Knudson, A.G. (1985). Hereditary cancer-oncogenes, and
antioncogenes. Cancer Res. 45: 225-235.
Koff, W.C., and Fann, A.V. (1986). Human tumor necrosis factor-
alpha kills herpesvirus - infected cells but not normal
cells. Lymphokine Res. 5: 215-221.
Kramer, D.L., Paul, B. , and Porter, C.W. (1985). Effect of
pretreatment with alpha-difluoromethylornithine on the
selectivity of methylgloxal bis(guanylhydrazone) for tumor
tissue in L1210 leukemic mice. Cancer Res. 45: 2512-2515.
Kronke, M., Schluter, C., and Pfizenmaier, K. (1987). Tumor
necrosis factor inhibits MYC expression in HL-60 cells at
the level of mRNA transcription. Proc. Natl. Acad. Sci. USA
84: 469-473.
Kull, F.C. Jr., and Cuatrecasas, P. (1981). Possible requirement
for internalisation in the mechanism of in. vitro
cytotoxicity in tumor necrosis sérum. Cancer Res. 41: 4885-
4890.
Kull, F.C. Jr. , Jacobjg, S., and Cuatrecasas, P. (1985). Cellular
receptor for ^^^I-labeled tumor necrosis factor: spécifie
binding, affinity labeling and relationship to sensitivity.
Proc. Natl. Acad. Sci. USA 82: 5756-5760.
Kuzumaki, N., Ogiso, Y., Oda, A., Fujta, H., Suzuki, H., Sato,
C. , and Mullauer, L. (1989). Résistance to Oncogenic
Transformation in revertant RI of Human ras-transformed
NIH3T3 cells. Mol. Cell. Biol. 9: 2258-2263.
Laemmil, U.K. (1970). Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227: 680-685.
LaiFatt, R.B. and Mak, S. (1982). Mapping of an adenovirus
function involved in the inhibition of DNA dégradation.
J. Virol. 42: 969-977.
Land, H., Parada, L.F., and Weinberg, R.A. (1983). Tumorigenic
conversion of embryo-fibroblasts requires at least two
cooperating oncogenes. Nature 304: 596-602.
Laster, S.M., Wood, J.G., and Gooding, L.R. (1988). Tumor
necrosis factor can induce both apoptic and necrotic forms
of cell lysis. J. Immunol. 141: 2629-2634.
88
Leof, E.B., Proper, J.A., and Moses, H.L. (1987). Modulation of
transforming growth factor type-beta action by activated ras
and c-mvc. Mol. Cell. Biol. 7: 2649-2652.
Lillie, J.W., Loewenstein, P.M., Green, M.R., and Green, M.
(1987). Functional domains of adenovirus type 5 ElA
proteins. Cell 50: 1091-1100.
Lillie, J.W., Green, M., and Green, M. (1986). An adenovirus ElA
protein région required for transformation and
transcriptional repression. Cell 46: 1043-1051.
Ling, V., Juranka, P.F., Endicott, J.A., Deuchars, K.L., and
Gerlach, J.H. (1988). Multidrug résistance and P-
glycoprotein expression. In: P.V. Wooley and K.D Tew
(eds.), Mechanism of Drug Résistance in Neoplastic cell, vol
9: pp 197-209. New York: Académie Press.
Liu, H.T., Baserga, R., and Mercer, W.E. (1985). Adenovirus type
2 activâtes cell cycle-dependent genes that are a subset of
those activated by sérum. Mol. Cell. Biol. 5: 2936-2942.
Malik, S., and Balkwill, F.R. (1988). Tumor necrosis Factor.
[Review]. Brit. Med. J. - Clin. Res. 296: 1214.
Mandell, J.-L., and Flintoff, W.F. (1978). Isolation of mutant
mammalian cells altered in polyamine transport. J. Cell.
Physiol. 97: 335-344.
Maniatis, T., Fritsch, E.F., and Sambrook, J. (ed.)., (1982).
In: Molecular cloning a laboratory manual. Cold Spring
Harbor Laboratory. Cold Spring Harbor, N.Y.
Mannel, D.N., Moore, R.N., and Mergenhagen, S.E. (1980).
Macrophages as a source of tumoricidal activity (Tumor-
necrotizing factor). Infect, and Immunity 30: 523-530.
Marmenout, A., Fransen, L., Tavernier, J., Van der Heyden, J.,
Tizard, R. , Kawashima, E., Shaw, A., Johnson, M.J., Semon,
D., Muller, R., Ruysschaert, M.R., Van Vliet, A., and Fiers,
W. (1985) . Molecular cloning and expression of human
tumor necrosis factor and comparison with mouse tumor
necrosis factor. Eur. J. Biochem. 152: 515-522.
Marshal., C.J., Franks, L.M., and Carbonell, A.W. (1977).
Markers of neoplastic transformation of epithial cell lines
derived from human carcinomas. J. Natl. Cancer Inst. 58:
1743-1751.
Maruyama, K., Hiwasa, T., and Oda, K. (1981). Characterization
of flat cells isolated from simian virus 40-transformed
mouse and rat cells which contain multiple copies of viral
genomes. J. Virol. 37: 1028-1043.
89
Mathey-Prevot, B., Shibuya, M., Samarut, J., and Hanafusa, H.
(1984). Revertants and partial transformants of rat
fibroblasts infected with Fujinama sarcoma virus. J. Virol.
50: 325-334.
Matthews, N. (1983). Tumour-necrosis factor from the rabbit. V.
Synthesis in vitro by mononuclear phagocytes from varions
tissues of normal and BCG-injected rabbits. Br. J. Cancer
44:418-424.
Mestan, J., Digel, W., Mittnacht, S., Hillen, H., Blohm, D.,
Moller, A., Racobsen, H., and Kirchner, H. (1986).
Antiviral effects of recombinant tumor necrosis factor in
vitro. Nature (London) 323: 816-819.
Mihich, E. (1967). Recent studies with new antileukemic
bis(guanylhydrazones). In: Takeda International conférence
on Cancer Chemotherapy. Gann monograph 2. A. Goldin,
K.Kaziwara, R. Kinosista and Y. Yammamura, eds. Maruzen Co.,
Tokyo, pp. 167-176.
Mihich, E., Dave, C., and Williams-Ashman, H.G. (1974).
Antiproliferative actions of the antileukemic agent,
methylglyoxal bis(guanylhydrazone (CH3-G): Relationships to
spermidine (SPD). Progress in Chemotherapy. Proceedings of
the 8th Int. Congress of Chemotherapy. G.K. Daikos, ed.
Athens, vol 3: pp845-848.
Mikles-Robertson, F., Feuerstein, B. , Dave, C., Porter, C.W.
(1979). The generality of methylglyoxal bis(guanylhydrazone)
induced mitochodrial damage and the dependence of this
effect on cell prolifération. Cance Res. 39: 1919-1926.
Montell, C. , Courtois, G., Eng, C., and Berk, A. (1984).
Complété transformation by adenovirus 2 requires both Ela
proteins. Cell 36: 951-961.
Montell, C. , Fisher, E.F., Caruthers, M.H., and Berk, A.J.
(1982). Resolving the functions of overlapping viral genes
by site-specific mutagenesis at an mRNA splice site. Nature
295: 380-384.
Moran, E., and Mathews, M.B. (1987). Multiple functional domains
in the adenovirus ElA gene. Cell 48: 177-178.
Moran, E., Zerler, B., Harrison, T.M., and Mathews, M.B. (1986).
Identification of separate domains in the adenovirus ElA
gene for immortalization activity and the activation of
virus early genes. Mol. Cell. Biol. 6: 3470-3480.
Morgan, D.M.L. (1987). Polyamines. Essays in Biochemistry
23:82-115.
Murphee, A.L., and Benedict, W.F. (1984). Retinoblastoma: dues
to human oncogenesis. Science 229: 1023-1033.
90
Nedwin, G.E., Naylor, S.L., Sakaguchi, A.Y., Smith, D., Jarret-
Nedwin, J. , Pennica, D., Goeddel, D.V., and Gray, P.W.
(1985). Human lymphotoxin and tumor necrosis factor genes:
structure homology and chromosomal localization. Nucleic
Acids Res. 13: 6361—6373.
Nevins, J.R. (1982) . Induction of the synthesis of a mammalian
70kD heat shock protein by the adenovirus ElA gene product.
Cell 29: 913-919.
Nevins, J.R. (1981). Mechanism of activation of early viral
transcription by the adenovirus ElA gene products. Cell 26:
213-220.
Nevins, J.R., Raychandhuri, P., Yee, A.S., Rooney, R.J., Kovesdi,
I. and Reichel, R. (1988). Transactivation by the
adenovirus ElA gene. Biochem. Cell Biol. 66: 578-583.
Noda, M., Selinger, Z., Scolnick, E.M., and Bassin, R.H. (1983).
Fiat revertants isolated from Kirsten sarcoma virus-
transformed cells are résistant to the action of spécifie
oncogenes. Proc. Natl. Acad. Sci. USA 80: 5602-5606.
Noda, M., Kitayana, H., Matsuzaki, T., Sugimoto, Y., Okayama, H.,
Bassin, R.H., and Ikawa, Y. (1989). Détection of genes with
a potential for suppressing the transformed phenotype
associated with activated ras genes. Proc. Natl. Acad. Sci.
USA 85: 1590-1594.
Norton, J.D., Cook, F., Roberts, P.C., Clewley, J.P., and Avery,
R.J. (1984). Expression of Kirsten murine sarcoma virus in
transformed nonproducer and revertant NIH/3T3 cells:
evidence for cell-mediated résistance to a viral oncogene in
phenotypic reversion. J. Virol. 50: 439-444.
O'Hara, B.M., Klinger, H.P., Curran, T., Zhang, Y.-D. and Blair,
.  D.G. (1987). Levels of fos. ets2. and mvb proto-oncogene
RNAs correlate with ségrégation of chromosome 11 or normal
cells and with suppression of tumorigenicity in Human cell
hybrids. Mol. Cell. Biol. 7: 2941-2946.
Oda, K., Masuda-Murata, M., Shiroki, K., and Handa, H. (1986).
Mitogenic activity of the adenovirus type 12 ElA gene
induced by hormones in rat cells. J. Virol. 58: 125-133.
Old, L.J. (1988). Tumor necrosis factor. Scientific American
258: 59-75.
Old, L.J. (1987). Tumor necrosis factor. Polypeptide mediator
network. Nature (London) 326: 330-331.
Oliff, A. (1988). The rôle of tumor necrosis factor (cachectin)
in cachexia. Cell 54: 141-142.
91
Ostrove, J.M., and Gifford, G.E. (1979). Stimulation of RNA
synthesis in L-929 cells by rabbit tumor necrosis factor.
Proc. Soc. Exp. Biol. Med. 160: 354-358.
Owen, R.D., and Ostrowski, M.C. (1987). Rapid and Sélective
altérations in the expression of cellular genes accompany
conditional transcription of Ha-v-ras in NIH 3T3 cells.
Mol. Cell. Biol. 7: 2512-2520.
Ozanne, B., and Vogel, A. (1974). Sélection of revertants of
Kirsten sarcoma virus transformed nonproducer Balb/3T3
cells. J. Virol. 14: 239-248.
Ozer, H.L., and Jha, K.K. (1977). Malignancy and transformation:
expression in somatic cell hybrids and variants. Adv.
Cancer Res. 25: 53-93.
Paabo, S., Severinsson, L., Andersson, M., Martens, I., Nilsson,
T., and Peterson, P.A. (1989). Adenovirus proteins and MHC
expression. Adv. Cancer Res. 52: 151-163.
Paeraatkul, V., De Stasio, P.R., and Taylor, M.W. (1988). A fast
and sensitive method for detecting spécifie viral RNA in
mammalian cells. J. Virol. 62: 1132-1135.
Parada, L.F., Land, H., Weinberg, R.A., Wolf, D., and Rotter, V.
(1984). Coopération between gene encoding p53 tumor antigen
and ras in cellular transformation. Nature 312: 649-651.
Peehl, D.M., and Stanbridge, E. J. (1981). Anchorage -
indépendant growth of normal human fibroblasts. Proc. Natl.
Acad. Sci. USA 78: 3053-3057.
Pegg, A.E., Kameji, T., Shirahata, A., Stanley, B., Madhubala,
R., and Pajunen, A. (1988). Régulation of mammalian S-
adenosylmethionine decarboxylase. Adv. Enz. Reg. 27: 43-55.
Pegg, A.E., Corti, A., William-Ashman, H.G. (1973). Paradoxical
enhancement of s-adenosylmethionine decarboxylase in rat
tissue following administration of the spécifie inhibitor
methylglyoxal bis(guanylhydrazone). Biochim. Biophys. Res.
Commun. 52: 696-701.
Pegg, A.E. (1984a). S-adenosyl decarboxylase. A brief review.
Cell Biochem. Function 2: 11-15.
Pegg, A.E. (1984b). The rôle of polyamine depletion and
accumulation of decarboxylated s-adenosylmethionine in the
inhibition of growth of SV-3T3 cells treated with
difluromethylornithine. Biochem. J. 224: 29-38.
Pegg, A.E. (1986). Recent advances in the biochemistry of
polyamines in eukaryotes. Biochem. J. 234: 249-262.
92
Pegg, A.E., Erwin, B.G., and Persson, L., (1985). Induction of
spermidine/spennine N'-acetyltransferase by methylglyoxal
bis(guanylhydrazone). Biochem. Biophys. Acta. 842: 11-118.
Pegg, A.E. and William-Ashman, H.G. (1969). On the rôle _of s-
adenosyl-L-methionine in the biosynthesis of spemidine by
rat prostate. J. Biol. Chem. 244: 582-693.
Pegg, A.E., Tang, K.-C., and Coward, J.K. (1982). Effects of S-
adenosyl-1,8-diamino-3-thiooctane on polyamine metabolism.
Biochemistry 21: 5082-5089.
Pegg, A.E., and McCann, P.P. (1982). Polyamine metabolism and
function. Am. J. Physiol. 243: C212-C221.
Pegg, A.E., Hibasami, H., Matsui, I., Bethell, D.R. (1981).
Formation and interconversion of putrescine and spermidine
in mammalian cells. Adv. Enz. Reg. 19: 427-451.
Pegg, A.E. (1988). Polyamine metabolism and its importance in
Neoplastic growth and as a target for chemotherapy. Cancer
Res. 48: 759-774.
Pennica, D. , Nedwin, G.E., Hayflick, J.S., Seeburg, P.H.,
Derynck, R., Palladino, M.A., Kohr, W.J., Aggarwal, B.B. and
Goeddel, D.V. (1984). Human tumor necrosis factor:
precursor structure, expression and homology to lymphotoxin.
Nature (London) 312: 724-729.
Perricaudet, M.G., Akusjarvi, G., Virtanen, A., and Pettersson,
U. (1979). Structure of two spliced mRNAs from the
transforming région of human subgroup C adenoviruses.
Nature 281: 694-696.
Persson, L., and Pegg, A.E. (1984). Studies of the Induction of
Spermidine/Spermine N'-acetyltransferase using a spécifie
antiserum. J. Biol. Chem. 259: 12364-12367.
Pilder, S., Logan, J. , and Shenk, T. (1984). Deletion of the
gene encoding the adenovirus 5 early région IB 21,000-
molecular weight polypeptide leads to dégradation of viral
and cellular DNA. J. Virol. 52: 664-671.
Pilder, S., Moore, M., Logan, J., and Shenk, T. (1986). The
adenovirus Elb-55K transforming polypeptide modulâtes
transport or cytoplasmic stabilization of viral and host
cell mRNAs. Mol. Cell. Biol. 6: 470-476.
Porter, C. W. and Sufrin, J.R. (1986). Interférence with
polyamine biosynthesis and/or function by analogs of
polyamines or methionine as a potential anticancer
chemotherapeutic strategy. Anticancer Res. 6: 525-542.
93
Poso, H., and Pegg, A.E. (1982). Comparison of S-
adenosylmethionine decarboxylase from rat liver and muscle.
Biochem. 21: 3116-3122.
Reid, T.R., Torti, F.M., and Ringold, G.M. (1989). Evidence for
two mechanisms by which tumor necrosis factor kills cells.
J. Biol. Chem. 264: 4583-4589.
Rodrigues, M.T., Palkonyay, L. , Sircar, S., Fleurent, J. ,
Dessureault, J., and Weber, J.M. (1987). Isolation and
uptake characteristics of adenovirus transformed cell
revertants résistant to the antiproliferative effects of
methylglyoxal bis(guanylhydrazone) . Biochem. Biophys. Res.
Commun. 147: 675-681.
Rosen, I. (1960). A hemagglutination-inhibition technique for
typing adenovirus. Am. J. Hygiene, 71: 120-128.
Rubin, B.Y., Smith, L.J., Hellermann, G.R., Lunn, R.M. ,
Richardson, N.K. and Anderson, S.L. (1988) . Corrélation
between the anticellular and DNA Fragmentating activities of
tumor necrosis factor. Cancer Res. 48L 6006-6010.
Ruddle, N.H. (1987). Tumor necrosis factor and related
cytotoxins. Immunology Today 8: 129-130.
Ruley, H.E. (1983). Adenovirus early région lA enables viral and
cellular transforming genes to transform primary cells in
culture. Nature 304: 602-606.
Rupniak, H. T., and Paul, D. (1980). Sélective killing of
transformed cells by exploitation of their defective cell
cycle control by polyamines. Cancer Res. 40: 293-297.
Rupniak, H.T., and Paul, D. (1978). Inhibition of spermidine and
spermine synthesis leads to growth arrest of rat embryo
fibroblasts in G-j^. J. Cell. Physiol. 94: 161-170.
Ryan, K.W., Christensen, J.B., Impériale, M.J., and Brockman,
W.W. (1985). Isolation of a simian virus 40 T-antigen-
positive, transformation-résistant cell line by indirect
sélection. Mol. Cell. Biol. 5: 3577-3582.
Sachs, L. (1987). Cell differentiation and By passing of Genetic
Defects in the suppression of Malignancy. Cancer Res. 47;
1981-1986.
Sacks, T.L., Hershey, E.J. and Stephenson, J.R. (1979). Abelson
murine leukemia virus-infected cell lines defective in
transformation. Virology 97: 231-240.
Sager, R. (1986). Genetic suppression of tumor formation: a new
frontier in cancer research. Cancer Res. 46: 1573-1580.
94
9Sambrook, J., Botchan, M., Gallimore, P., Ozanne, B.
Pettersson, U., Williams, J.F., and Sharp, P.A. (1975).
Viral DNA sequences in cell transformed by simian virus 40,
adenovirus type 2 and adenovirus type 5. Cold Spring Harbor
Symp. Quant. Biol. 39: 615-632.
Samid, D., Flessate, D.M., and Friedman, R.M. (1987).
Interferon-induced revertants of ras-transformed cells:
cells: résistance to transfomation by spécifie oncogenes and
retransformation by 5-azacytidine. Mol. Cell. Biol. 7:
2196-220.
Sarnow, P., Ho, Y-S., Williams, J., and Levine, A.J. (1982).
Adenovirus Elb 58Kd tumor antigen and SV40 Large T antigen
are physically associated with the same 54Kd cellular
protein in transformed cells. Cell 28: 387-394.
Satomi, N., Haranaka, K., and Kunii, 0. (1981). Research on the
production site of tumour necrosis factor (TNF). Jpn J.
Exp. Med. 56: 317-322.
Schaefer, R., lyer, J., Iten, E., and Nirkko, A. (1988). Partial
reversion of the transformed phenotype in HRAS - transformed
tumorigenic cells by transfer of a human gene.
Proc. Natl. Acad. Soi. USA 85: 1590-1594.
Schmid, D.A., Hornung, R., McGrath, K.M., Paul, N., and Ruddle,
N.H. (1987). Target cell DNA fragmentation is mediated by
lymphotoxin and tumor necrosis factor. Lymphokine Res. 6:
195-202.
Schmid, D.S., Tite, J.P., and Ruddle, N.H. (1986). DNA
fragmentation: manifestation of target cell destruction
mediated by cytotoxic T-cell lines, lymphotoxin-secreting
helper T-cell clones, and cell-free lymphotoxin-containing
supernatant. Proc. Natl. Acad. Sci. USA 83: 1881-1885.
Schneider, J.F., Fisher, F., Gooding,. C.R., and Jones, N.C.
(1987). Mutational analysis of the adenoviruses ElA gene:
the rôle of transcriptional régulation in transformation.
EMBO J. 6: 2053-2060.
Schutze, S., Scheurich, P., Schluter, C., Ucer, U., Pfizenmaier,
K., and Kronke, M. (1988). Tumor necrosis factor-induced
changes of gene expression in U937 cells. Differentiation-
dependent plasticity of the responsive state. J. Immunol.
140: 3000-3005.
Schwab, M., Varmus, H.E., and Bishop, J.M. (1985). Human N-myc
gene contributes to neoplastic transformation of mammalian
cell in culture. Nature 316: 160-162.
95
Shear, M.J., Turner, F.C., Perrault, A., and Shovelton, J.
(1943). Chemical treatment of tumors. V. Isolation of the
hemorrhage-producing fraction from serratioa marcescens
(Bacillus prodigiosus) culture filtrate. J. Natl. Cancer
Inst. 29: 1169-1175.
Shirahata, A., and Pegg, A.E. (1985). Régulation of s-
adenosylmethionine decarboxylase activity in rat liver and
prostate. J. Biol. Chem. 260: 9583-9588.
Sircar, S., Palknoyay, L., Rodrigues, M., Allaire, S., Horvath,
J., Thirion, J-P., and Weber, J. (1987). Isolation of
variants résistant to methylglyoxal bis(guanylhydrazone)
from adenovirus-transformed rat cells. Cancer Res. 47:
1339-1343.
Sircar, S., Rodrigues, M., and Weber, J. (1988). Résistance to
retransformation by adenovirus but not by heterologous
oncogenes in an El-positive transformation revertant cell
line may be mediated by a cellular function. Oncogene 3:
725-728.
Sircar, S., and Weber, J.M. (1988). Nomnalization of epidermal
growth factor receptor and transforming growth factor
production in drug résistance variants derived from
adenovirus transformed cells. J. Cell. Physiol. 134: 467-
472.
Siva Raman, L. , Subramanian, S., and Thimmapaya, B. (1986).
Identification of a factor in Hela cells spécifie for an
upstream transcriptional control sequence of an ElA-
inducible adenovirus promoters and its relative abundance in
infected and uninfected cells. Proc. Natl. Acad. Sci. USA
83: 5914-5918.
Smith, R.A., and Baglioni, C. (1987). The active form of tumor
necrosis factor is a trimer. J. Biol. Chem. 262: 6951-6954.
Spandidos, D.A., and Anderson, M.L.M. (1987). A study of
mechanism of carcinogenesis by gene transfer of oncogenes
• into mammalian cells. Mutation Res. 185: 271-291.
Spies, T., Morton, C.C., Nedospasov, S.A., Fiers, W. , Pious, D.,
and Strominger, J.L. (1986). Genes for tumor necrosis
factors alpha and beta are linked to the human major
histocompatibility complex. Proc. Natl. Acad. Sci. USA 83:
8699-8702.
Stabel, S., Argos, P., and Philipson, L. (1985). The release of
growth arrest by microinfection of adenovirus ElA DNA. EMBO
J. 4: 2329-2336.
96
Stanbridge, E.J., Der, C.J., Doersen, C.-J., Nishimi, R.Y.,
Peehl, D.M., Weissman, B.E. and Wilkinson, S.E. (1982).
Human cell hybrids: analysis of transformation and
tumorigenicity. Science 215; 252-259.
Stephenson, J.R., Reynolds, R.K., and Aaronson, S.A. (1983).
Characterization of morphologie revertants of murine and
avian sarcoma virus-transformed cells. J. Virol. 11: 218-
222.
Stillman, B. (1986). Functions of the adenovirus ElB tumor
antigens. Cancer Surv. 5: 389-404.
Subramanian, R., Kappuswamy, N., Nasr, R.J., and Chinnadurai, G.
(1988). An N-terminal région of adenovirus ElA essentiel
for cell transformation and induction of an epithial growth
factor. Oncogene 2: 105-112.
Subramanian, T., Kuppuswamy, M., Gysbers, J., Mak, S., and
Chinnadurai G. (1984). 19K-Da tumor antigen coded by early
région ElB of adenovirus 2 is required for efficient
synthesis and for protection of viral DNA. J. Biol. Chem.
259: 11777-11783.
Sugarman, B.J., Aggarwal, B.B., Hass, P.E., Figari, I.S.,
Palladino, M.A. Jr., and Shepard, H. M. (1985). Recombinant
human tumor necrosis factor-a: effects on prolifération of
normal and transformed cells in vitro. Science 230: 943-
945.
Tabor, C.W. , and Tabor, H. (1984). Polyamines. Ann. Rev.
Biochem. 53: 749-790.
Talbot, N., Hankey, P., Jiang, B. , Yanagihara, K., deVilliers,
J., Bassin, R.H., and Benade, L.E. (1988). A system for
deriving revertants of oncogene-transformed human cells.
Cytogenet. Cell Genet. 48: 112-116.
Till, J.E., Baker, R.M., Brunette, D.M., Ling, V., Thompson, L.H.
and Wright, J.A. (1973). Genetic régulation of membrane
function in mammalian cells in culture. Fed. Proc. 32: 29-
33.
Tooze, J. (1981). Molecular Biology of tumor viruses, 2nd ed.
Part 2, DNA tumor viruses. Cold Spring Harbor, New YorK.
Tracey, K.J., Lowery, S. F., and Cerami, A. (1988). Cachectin: A
hormone that triggers acute shock and chronic Cachexia. J.
Infections Diseases. 157: 413-420.
Trentin, J.J., Yabe, Y., Taylor, G. (1962). The quest for human
cancer viruses. Science 137: 835-841.
97
Turner, M., Londei, M., and Feldmann, M. (1987). Human T cells
frora auto-immune and normal individuals can produce tumour
necrosis factor. Eur. J. Immunol. 17: 1807-1814.
van der Eb, A. J. , and van Kestern, L.W. (1966). Structure and
molecular weight of the DNA of adenovirus type 5. Biochem.
Biophys. Acta 129: 441-444.
van den Elsen, P., Houweling, A., and van der Eb, A.J. (1983a).
Expression of région ElB of human adenovirus in the absence
of région ElA is not sufficient for complété transformation.
Virology 128: 377-390.
Varmus, H.E., Quintrell, N., and Wyke, J. (1981). Revertants of
an ASV-transformed rat cell line have lost the complété
provirus or sustained mutations in src. Virology 108; 28-
46.
Velcich, A., and Ziff, E. (1985). Adenovirus ElA proteins
repress transcription from the SV40 early promoters. Cell
65: 826-839.
Vilcek, J., Palombella, V.J., Henriksen-Destefano, D. , Swenson,
C., Feinman, R. , Hirai, M., and Tsujimoto, M. (1986).
Fibroblast growth enhancing activity of tumor necrosis
factor and its relationship to other polypeptide growth
factors. J. Exp. Med. 163: 632-643.
Virtanen, A., Pettersson, U., LeMoullec, J.M., Tiollais, P., and
Perricaudet, M. (1982) . Différent mRNA structures are
transcribed from the transforming région of higly and non-
oncogenic human adenoviruses. Nature (London) 295: 705-
707.
Virtanen, A., and Petterson, U. (1985). Organization of early
région IB of human adenoviruses type 2: identification of
four differentially spliced mRNAs. J. Virol. 54:383-391.
Vogel, A. and Pollack, R. (1974). Methods for obtaining
revertants of transformed cells. Methods Cell Biol. 8: 75-
91.
Wang, A.M., Creasey, A.A., Ladner, M.B., Lin, L.S., Strickler,
J., Van Arsdell, J.N., Yamamoto, R. and Mark, D.F. (1985).
Molecular cloning of the complementary DNA for human tumor
necrosis factor. Science 228: 149-154.
Warren, L. , Fuhrer, J.P., and Buck, C.A. (1973). Surface
glycoproteins of cells before and after transformation by
oncogenic viruses. Fed. Proc. 32: 80-85.
Weber, J.M., Sircar, S., Fleurent, J., and Hamel, M. (manuscript
submitted). Drug induced revertants of adenovirus
transformed cells. Retransformation by 5-azacytidine
without réactivation of Ela.
98
Weissman, B.E., Saxon, P.J., Pasquale, S.R., Jones, G.R., Geiser,
A.G., Stanbridge, E.J. (1987). Introduction of a normal
human chromosome 11 into a Wilm's tumor cell line controls
its tumorigenic expression. Science 236: 175-179.
Weissman, B.E., and Aaronson, S. A. (1983). BALB and Kirsten
Marine Sarcoma Viruses. Alter growth and Differentiation
of EGF-dependent Balb/c mouse epidermal keratinocyte lines.
Cell 32: 599-606.
White, E., Faha, B., and Stillman, B. (1986). Régulation of
adenovirus gene expression in Human W138 cells by an Elb-
encoded tumor antigen. Mol. Cell. Biol. 6: 3763-3773.
White, E., Grodzicker, T., and Stillman, B. (1984b). Mutations
in the gene encoding the adenovirus Elb 19K tumor antigen
cause dégradation of chromosomal DNA. J. Virol. 52: 410-
419.
White, E., Blose, S.H., and Stillman, B. (1984a). Nuclear
envelope localization of an adenovirus tumor antigen
maintains the integrity of cellular DNA. Mol. Cell. Biol.
4: 2865-2875.
White, E., Denton, A., and Stillman, B. (1988). Rôle of the
adenovirus Elb 19,000-Dalton tumor antigen in régulation of
early gene expression. J. Virol. 62: 3445-3454.
Whyte, P., Buchkovich, K.J., Horowitz, J.M., Friend, S.H.,
Raybuck, M., Weinberg, R.A., and Harlow, E. (1988a).
Association between an oncogene and an antioncogene: the
adenovirus ElA proteins bind to the retinoblastoma gene
product. Nature 334: 124-129.
Whyte, P., Ruley, H.E., and Harlow, E. (1988b). Two régions of
the adenovirus early région lA proteins are required for
transformation. J. Virol. 62: 257-265.
Whyte, P., Williamson, N.M., and Harlow, E. (1989). Cellular
targets for transformation by the adenovirus ElA proteins.
Cell 56: 67-75.
Wigler, M., Sweet, R. , Sim, G.K., Wold, B. , Pellicer, A., Lacy,
E., Maniatis, T. (1979). Transformation of mammaliam cells
with genes from procaryotes and eucaryotes. Cell 16: 777-
785.
Williams-Ashman, H.G., and Schenone, A. (1972). Methylglyoxal
bis(guanylhydrazone) as a potent inhibitor of mammalian and
yeast s-adenosylmethionine decarboxylase. Biochem. Biophys.
Res. Commun. 46: 288-295.
99
Williams-Ashman, G.H., and Seidenfeld, J. (1986). Aspects of the
biochemical pharinacology of methylglyoxal bis(guanyl-
hydrazone). Biochem. Pharmacol. 35: 1217-1225.
Wilson, M., Fraser, N., Darnell, J. (1979). _ Mapping of RNA
initiation sites by high doses of UV irradiation. Evidence
of three independent promoters within the left 11% of the
Ad2 genome. Virology 94: 175-184.
Wilson, J.B., Hayday, A., Courtneidge, S., and Fried, M. (1986).
A frameshift at a mutational hotspot in the polyoma virus
early région generates two new proteins that define T-
antigen functional domains. Cell 44: 477-487.
Wiseman, A., Kramer, D.L., and Porter, C.W. (1983). Isolation
and uptake characteristics of human cell variants résistant
to the antiproliferative effects of methylglyoxal
bis(guanylhydrazone). Cancer Res. 43: 5937-5942.
Wong, G.H.W., and Goeddel, D.V. (1988). Induction of manganous
superoxide dismutase by tumor necrosis factor: Possible
protective mechanism. Science 242: 941-242.
Wong, G.H.W., and Goeddel, D.V. (1986). Tumour necrosis factor
alpha and.beta inhibit virus replication and synergize with
interferons. Nature (London) 323: 819-822.
Yabe, Y. (1964). Antibody to adenovirus type 12 among infants.
Lancet 1: 1447-1448.
Yancopoulous, G.D., Nisen, P.O., Tesfaye, A., Kohi, N.E.,
Goldfarb, M.P., and Alt, F.W. (1985). N-myc can cooperate
with ras to transform normal cells in culture. Proc. Natl.
Acad. Sci. USA 82: 5455-5459.
Yarden, E., and Kimichi, A. (1986). Tumor necrosis factor
reduces c-myc .expression and coopérâtes with interferon -
gamma in Hela cells. Science 234: 1419-1421.
Yee, S., and Branton, P.E. (1985). Détection of cellular
proteins associated with human adenovirus type 5 early
région lA polypeptides. Virology 147: 142-153.
Zarbl, H., Latreille, J., and Jolicoeur, P. (1987). Revertants
of v-fos-Transformed fibroblasts have mutations in cellular
genes essential for transformation by other oncogenes. Cell
51: 357-369.
Zerler, B., Moran, B., Maruyama, K., Moomaw, J. , Grodzicker, T.,
and Ruley, H.E. (1986), Adenovirus ElA coding sequence that
enable ras and pmt oncogenes to transform cultured primary
cells. Mol. Cell. Biol. 6: 887-899.
100
Zerler, B. , Roberts, R.J., Mathews, M.B., and Moran, E. (1987).
Différent functional domains of the adenovirus ElA gene are
involved in régulation of host cell cycle products. Mol.
Cell. Biol. 7: 821-829.
101
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Reversion o£ transformation and résistance to the cytotoxic drug
are two independent phenomenon
Most of the clones studied, the résistance to MGBG is due to a
decrease in the uptake of the drug
Fusion studies show this phenotype is récessive. Since two
clones résistant to MGBG are capable of complementing, suggests
the résistance is controled by more than one locus.
The loss of the transfomed phenotype for majority of the clones
studied is due to an inactivation or loss of the adeno El
transforming gene.
However, G2, the only revertant clone possess a cellular
mutât i on.
This mutation is dominant over the adenovirus El transforming
gene.
ElA induced TNF susceptiblity, but the transformed phenotype is
not required.
ElA and RB protein complexes were observed in ail clone analysed
and the presence of this complex suggests it may be necessary but
not sufficient for cell transformation.
BIOCHEMICAL CHARACTERIZATION OF MGBG-RESISTANT CELL LINES
Drug résistance in somatic cells may operate on three différent
phenomena:
- target component may be elevated
- cellular target may alter its affinity for the drug
- cellular influx/efflux may affected
Target component of MGBG
- S-adenosylmethionine decarboxylase (SAMDC)
one of the key enzyme that régulâtes the mammalian polyamine
bi osynthe is
- putrescine-activated enzyme and this enzyme is présent in minute
amounts in normal and malignant cells
- rôle is to provide an aminopropyl donor for the formation of
spermidine and spermine by decarboxylating s-adenosylmethionine
MGBG (Methylglyoxal bis (guanylhydrazone)
is a drug used to treat cancer patients
irst reported by Freedlander and French in 1958
wlth the polya.lne
posltlvaly charged at phys.ological pH, thus haa several blndlng
contains several domains:-
F4 - a rat embryonlt brain cell line tranformed by the adencvirus type2
tranaforainjregion ,E1,
this cell line semipermissive to adencvirus infection
2. Reversion of Transformation
différences between the transformed state and the normal state can be
distinguished by;-
isolating transformation revertants from a population of
transformed cells that lack at least one of the transformation
properties.
varions procédures bave been used:-
- cloning from culture
- selecting cells surviving in the presence of a cytotoxic drug
- using a fluorescence sorting technique
Three types of £lat revertants produce from transformed cells by spécifie
oncogenes
1 - revertant due to inactivation of the oncogene(s)
2 - revertant due to inactivation of the cellular target genes
3 - revertant due to activation of tumor suppressor genes
1. Cellular genes are involved in transformation
Several approaches illustrate the existence of these gcnes
- altérations in cellular gene expression following transformation
-  isolation of cryptic transformants
- cellular protein binding directly to viral oncoproteins
CARCINOGENESIS
Malignant cell transformation is a multistep process.
More than one pathway leads to the transformation of the coll.
Little is known about cellular interaction of the oncoproteins
and the mechansim by which they transform cells.




























